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ABSTRACT 
An over-accumulation of triacylglycerol (TAG) within the liver results in 
non-alcoholic fatty liver disease (NAFLD), which may progress to more severe 
states including cirrhosis and fibrosis, finally leading to liver injury and death. In 
most cases, the etiology of NAFLD is not completely understood but has been 
primarily linked to the occurrence of insulin resistance, which often accompanies 
obesity, dyslipidemia and Type 2 Diabetes. Previously, our laboratory discovered 
that adipose triglyceride lipase (ATGL) catalyzes TAG hydrolysis in the liver and 
partitions the hydrolyzed fatty acids to oxidative pathways.  Additionally, ATGL 
promotes fatty acid oxidation in part through its induction of peroxisome 
proliferator activated receptor-α (PPAR-α) and its co-activator PPAR-γ 
coactivator-1α (PGC-1α) signaling. The objective of this work is to further 
elucidate the mechanisms underlying ATGL’s effects on lipid metabolism and 
signaling. Herein, we show that ATGL activates the protein deacetylase sirtuin 1 
(SIRT1) which subsequently deacetylates and activates PGC1- α and PPAR-α to 
promote transcriptional regulation of mitochondrial biogenesis and FA oxidation. 
ATGL preferentially cleaves FA oleate from TAG to induce SIRT1 enzyme 
activity in a dose-dependent manner; other FA species had no effect.  Moreover, 
ATGL requires SIRT1 for the induction of PGC-1α/PPAR-α target genes and 
oxidative metabolism.  ATGL also mediates the effect of β-adrenergic signaling 
on SIRT1 activity and PGC-1α and PPAR-α target gene expression.  This work is 
the first to identify an endogenous activator of SIRT1 that couples β-adrenergic 
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signaling and lipolysis activation to enhanced transcriptional regulation of 
oxidative metabolism. 
In addition to increased SIRT1 activity and downstream oxidative 
metabolism, our research reveals that ATGL activation induces a cellular 
recycling process called autophagy. In particular, ATGL requires functional 
autophagy to mediate its effects on lipid depletion in a SIRT1 dependent manner. 
In addition, ATGL requires SIRT1 to exert its effects on TAG turnover via 
autophagy.  In addition, we show that ATGL mediates FA secretion via the 
lysosome, as confirmed in both in vitro and in vivo models, in response to fasting. 
Interestingly, these effluxed FAs undergo a reuptake process before being 
oxidized or reesterified into existing TAG depots. Overall, these data challenge 
the current dogma of hepatic lipid metabolism and advance our understanding of 
lipid droplet biology. 
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CHAPTER 1 
 
 
 
The Role of Hepatic Lipolysis in the 
regulation of Lipophagy and subsequent 
mitigation of Fatty Liver Disease  
 
 
Aishwarya Sathyanarayan wrote this chapter in its entirety. 
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Hepatic lipid metabolism and Non-Alcoholic Fatty Liver 
disease (NAFLD) 
The liver is an integral organ involved in lipid metabolism and is an 
important contributor to both the synthesis, uptake and oxidation of fatty acids 
(FAs). FAs serve as the building blocks for more complex lipids and, when stored 
as triacylglycerol (TAG), represent the major storage of energy. Hepatic FAs are 
primarily obtained through de novo lipogenesis, lipoprotein remnant uptake and 
adipose tissue derived plasma non-esterified fatty acids (NEFA) (Nguyen et al., 
2008). Because the liver does not serve as a major storage depot for fat, 
concentration of hepatic TAGs is low under normal physiological conditions.  
Despite the low concentration, there is considerable trafficking of both 
TAGs and FAs in and out of the liver in response to a fed or fasted state 
(Kawano and Cohen, 2013). Hepatic TAG content is balanced through processes 
involved in FA uptake, lipogenesis, lipolysis, oxidation and very low density 
lipoprotein (VLDL) export (Nguyen et al., 2008). The liver takes up serum NEFAs, 
which enter the cells via transporters such as FA transport proteins (FATP) or 
clusters of differentiation 36 (CD36) receptors. NEFAs are subsequently 
activated by a member from the families of acyl-CoA synthetases (ACSLs) or 
FATPs (Nguyen et al., 2008). Several isoforms of ACSL have been identified and 
each plays a significant role in determining the fate of a particular acyl-CoA by 
channeling the species towards lipid synthesis or oxidation (Nguyen et al., 2008).  
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Once excess serum free FAs are taken up by hepatocytes and, they are 
stored as TAG within lipid droplets. Over-accumulation of lipid droplets within 
hepatocytes eventually results in hepatic steatosis, which may develop as a 
consequence of reduced disposal of FAs via decreased β-oxidation, very low-
density lipoprotein secretion (VLDL), or enhanced uptake or synthesis of FA 
(Kawano and Cohen, 2013).  The most common liver disease is non-alcoholic 
fatty liver disease (NAFLD), which may progress from a mild hepatic steatosis to 
more severe states including cirrhosis and fibrosis, eventually resulting in 
hepatocyte injury and death (Fabbrini et al., 2010; Yoneda et al., 2008) 
Despite the severe consequences of NAFLD, in most cases, the etiology 
of NAFLD is not completely understood. It has been primarily linked to the 
occurrence of insulin resistance that often accompanies obesity, dyslipidemia 
and Type 2 Diabetes (Angulo, 2002; McCullough, 2004). NAFLD is frequently 
characterized by increased hepatic TAG accumulation in the absence of 
significant alcohol consumption and has been associated with numerous 
metabolic diseases including insulin resistance, Type 2 Diabetes and obesity 
(Utzschneider and Kahn, 2006). Specifically, insulin resistance in the adipose 
tissue results in increased TAG breakdown and release of NEFA, which results in 
increased hepatic uptake. This metabolic state also results in higher levels of 
circulating insulin, which promotes increased hepatic TAG synthesis and 
decreased mitochondrial fatty acid oxidation (Angulo, 2002). Other relevant 
causes that could contribute to NAFLD and cirrhosis include nutritional status of 
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the individual, drug-toxicity, hepatitis C virus infection and inflammatory disorders 
such as Inflammatory Bowel Syndrome and Crohn’s disease (Cave et al., 2007; 
McCullough, 2004). 
NAFLD is present in approximately one-third of the general population 
(Charlton et al., 2011; Francque et al., 2016). The prevalence is higher in obese 
populations with BMI ≥ 30, and there is an increasing incidence of non-alcoholic 
steatohepatitis (NASH) in morbidly obese individuals with BMI ≥ 40 (Dixon et al., 
2001; García-Monzón et al., 2000). Given the widespread prevalence and 
debilitating consequences of NAFLD to other metabolic disorders, it is of 
paramount importance to further study its pathogenesis.   
 
TAG hydrolysis- discovery of ATGL and its regulation 
The majority of scientific literature has focused on the role of lipid 
synthesis in the pathophysiology of NAFLD. Several recent advances have 
looked at the contribution of TAG catabolism to NAFLD (Jha et al., 2013; Ong et 
al., 2011). Lipolysis is a critical physiological process involved in breaking down 
TAG to release free fatty acids and glycerol and is primarily governed by the 
energy status of the body.  
In the fed-state when the body is replete with energy resources, insulin 
inhibits TAG catabolism and promotes its synthesis (Klop et al., 2013). During 
fasting, the body relies on its stored energy reserves such as TAG depots and 
lipolysis is initiated via catecholamine mediated β-adrenergic stimulation. Hepatic 
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TAG hydrolysis primarily serves to provide FA substrates for mitochondrial β-
oxidation, signaling, and VLDL assembly for TAG export (Quiroga and Lehner, 
2012). On the other hand, white adipose tissue (WAT) exhibits the highest 
lipolytic activity and is responsible for releasing FAs into circulation during times 
of starvation/fasting.  
Historically, lipolysis within the WAT was believed to be catalyzed by two 
major lipases, namely hormone-sensitive lipase (HSL) and monoglyceride lipase 
(MGL). HSL has catalytic activities towards both TAG and diacylglycerol (DAG) 
(Quiroga and Lehner, 2012). Thus, HSL hydrolyzes TAG to yield DAG and 
further breaks DAG to obtain a monoacylglyceride (MAG) moiety which is 
eventually hydrolyzed by MGL to liberate the final FA, leading to glycerol release. 
However, the hypothesis that HSL was the major lipase catalyzing the 
breakdown of TAG and DAG (Small et al., 1989; Yeaman, 1990) in most tissues 
including adipose tissue, skeletal muscles and the liver was questioned when 
genetic ablation of HSL failed to eliminate lipolysis in adipocytes (Lafontan and 
Langin, 2009; Osuga et al., 2000). This paved way to the discovery of a new 
lipase by three separate scientific groups in 2004, and this enzyme was termed 
adipose triglyceride lipase (ATGL) (Zimmermann et al., 2004), desnutrin (Villena 
et al., 2004) or phospholipase A2 (Jenkins et al., 2004).  
ATGL selectively performs the first step in TAG hydrolysis, yielding DAG and free 
FAs (Zimmermann et al., 2004).  Phylogenetic ancestral analysis revealed ATGL 
to contain a patatin-like phospholipase (PNPLA) domain, and it was thus 
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classified under a group of five phospholipases PNPLA 1-5 (Rydel et al., 2003). 
This group of enzymes contains a patatin-domain that encodes the major 
glycoprotein in potatoes with known DAG and MAG activity but not specific TAG 
hydrolase activity (Wilson et al., 2006; Zechner et al., 2005). However, ATGL 
was found to exhibit minimal or no activity to other lipid species such as DAG, 
MAG, and acylesters like retinyl esters and cholesteroyl esters (Zimmermann et 
al., 2004).  
The human and mouse genes for ATGL encode proteins with 504 and 486 
residues, respectively, and share 84% amino acid identity. The predominant 
regions of low sequence conservation are clustered around amino acid residue 
260 and the C-terminal end of the protein (Lass et al., 2011).  Sequence 
similarities predict that the N-terminal half of ATGL is an α/β-fold hydrolase fold 
protein, common to a number of hydrolytic enzymes and belonging to the 
superfamily of patatin-like phospholipases (Rydel et al., 2003; Wilson et al., 
2006). It has been postulated that a hydrophobic stretch within the C-terminus 
represents a lipid binding region that is involved in regulating enzyme activity 
(Kobayashi et al., 2008; Schweiger et al., 2008). Additionally, human ATGL can 
be phosphorylated on two sites, serine 404 and serine 428, though these sites 
are not modified by the classical lipolytic signal protein kinase A (Bartz et al., 
2007; Zimmermann et al., 2004). Furthermore, recent evidence indicates that 
adipose-specific AMP-activated protein kinase (AMPK) ablation has defective 
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phosphorylation of serine 406, lowering basal lipolysis in adipose tissue (Kim et 
al., 2016) 
Further elucidation of the physiological function of ATGL was obtained 
through the ATGL knockout (Atgl(-/-)) mouse model (Haemmerle et al., 2006). 
Atgl(-/-) mice exhibited increased accumulation of neutral lipid in most tissues, 
particularly WAT and heart, suggesting an essential role this enzyme plays in 
cellular TAG catabolism. This increased lipid accumulation was accompanied by 
a concomitant increase in body weight gain with no changes in food intake or 
lean body mass measurements (Haemmerle et al., 2006). Furthermore, β-
adrenergic stimulated lipolytic capacity and TAG hydrolase activity were 
drastically reduced in the ATGL deficient WAT, liver, and skeletal muscle 
(Haemmerle et al., 2006). The excessive TAG accumulation coupled with 
impaired TAG mobilization in the heart causes severe myopathy in cardiac 
muscle and defective thermogenesis in the brown adipose tissue (BAT) 
(Haemmerle et al., 2006). This excessive TAG accumulation in the heart results 
in cardiac dysfunction and premature death of ATGL-deficient mice (Haemmerle 
et al., 2006).  
Interestingly, despite the increased TAG stores due to impaired 
degradation, ATGL-deficient mice had lower plasma FA, TAG, and cholesterol 
concentrations compared to HSL-deficient mice (Haemmerle et al., 2006). 
Further elucidation of hepatic ATGL has revealed this lipase promotes TAG 
breakdown without affecting VLDL secretion (Ong et al., 2011). More specifically, 
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manipulating hepatic ATGL function failed to influence TAG secretion despite 
significantly altering fatty acid oxidation with concomitant changes in peroxisome 
proliferator-activated receptor α (PPAR-α) target genes (Ong et al., 2011). Taken 
together, these findings indicate that ATGL is the rate-limiting enzyme that 
hydrolyzes TAG, while HSL primarily catalyzes degradation of DAG followed by 
MGL that specifically targets MAG for breakdown (Haemmerle et al., 2006; 
Yeaman, 1990) 
Regulation of ATGL activity is of immense research interest and has only 
been partially elucidated. ATGL mRNA levels are increased during fasting and 
repressed during re-feeding (Oliver et al., 2012; Villena et al., 2004). Additionally, 
insulin has also been shown to suppress lipolysis by down-regulating the 
expression of ATGL, which may account for some of the fasting/re-feeding 
regulation (Kolditz and Langin, 2010). ATGL activity is further increased by an 
activator protein, comparative gene identification-58 (CGI-58- also known as α/β 
hydrolase domain containing protein 5) (Lass et al., 2011). An important 
regulatory mechanism for ATGL involves the activation of the enzyme upon 
interaction with CGI-58 with maximal stimulation obtained at approximately a one 
to one stiochiometry of the enzyme and activator protein (Lass et al., 2006).  
Recently, G0/G1 switch protein 2 (GOS2) protein was found to selectively inhibit 
ATGL (Yang et al., 2010). The mechanistic involvement of GOS2 in the cell-cycle 
remains unclear. However, it has been found to be expressed in cells 
transitioning from the G0 to G1 phase of the cell cycle (Russell and Forsdyke, 
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1991).  GOS2 has been shown to directly interact with the N-terminal patatin 
domain of ATGL and this interaction does not directly compete with the binding of 
CGI-58, which also interacts with the N-terminal region of ATGL (Klar et al., 
1981; Russell and Forsdyke, 1991). This interaction has been further 
corroborated by co-immunoprecipitation experiments demonstrating that CGI-58 
does not affect the interaction between GOS2 and ATGL (Yang et al., 2010). 
Despite sharing the N-terminus of ATGL as a binding site, the above 
observations suggest that GOS2 and CGI-58 do not compete in the regulation of 
ATGL activity. ATGL has also been reported to be a receptor of pigment 
epithelium-derived factor (PEDF), a multifunctional glycoprotein involved in 
neuronal survival and differentiation (Notari et al., 2006). PEDF binds to ATGL 
and increases its TAG hydrolase activity, which is supported by data showing 
increased lipid accumulation in PEDF-null hepatocytes compared to the controls 
(Chung et al., 2008). Reversal of this steatosis was observed upon PEDF 
restoration, highlighting the importance of PEDF is regulating ATGL activity 
(Chung et al., 2008).  
TAG hydrolysis generates DAGs and FAs and the resulting DAG can exist 
in three stereochemical isoforms. ATGL-mediated lipid catabolism specifically 
cleaves the FA at the sn-2 position of the TAG molecule generating a sn-1, 3 
DAG isoform (Eichmann et al., 2012). In the presence of its co-activator CGI-58, 
ATGL additionally cleaves the FA at sn-1 position resulting in sn-2, 3 DAG 
(Eichmann et al., 2012). More importantly, DAG isoforms obtained through ATGL 
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hydrolysis are not involved in phospholipid synthesis or activation of protein 
kinase C, which is implicated in insulin resistance and other signaling pathways 
(Eichmann et al., 2012). Interestingly, diacylglycerol-O-acyltransferase 2 (DGAT-
2), involved in DAG re-esterification to TAG, preferentially esterifies sn-1, 3 DAG 
(Eichmann et al., 2012). Thus, ATGL and DGAT-2 act coordinately in the 
hydrolysis and re-esterification of TAG (Eichmann et al., 2012).  This 
stereo/regioselectivity of ATGL shows the importance of this lipase in DAG 
metabolism and signaling.  Although DAG isoforms obtained through ATGL-
derived TAG hydrolysis have been well characterized, little is known on the 
signaling role of specific FA species generated through the same lipolytic 
process. 
 
Adapted from Matt, M.J., & Steinberg, G.R. (2008); 414(3), 313-325 
Figure 1: In the basal state, ATGL is localized to the LD and not in proximity with 
CGI-58. Upon stimulus, phosphorylation of perilipin dissociates CGI-58 which 
translocates to ATGL and promotes TAG hydrolysis. 
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Introduction to Sirtuins - Structure and regulation 
Sirtuins are Class III NAD+ dependent histone/protein deacetylases and/or 
mono-ADP-ribosyltransferases found in organisms ranging from microbes to 
humans. They comprise a unique group of enzymes, relying on nicotinamide 
adenine dinucleotide (NAD+) as an essential cofactor linking their activity to 
cellular metabolic status (Kaeberlein et al., 1999). Originally found in yeast, Sir2 
was discovered as a silencing factor and has been shown to mediate the effects 
of calorie restriction on lifespan extension (Jeggo, 1998). In addition, Sir2 
participates in repression of transcriptional activity via gene silencing and in DNA 
double-strand break (DSB) repair (Tanny et al., 1999). Gene silencing is a type of 
DNA inactivation involved in the regulation of gene expression and a major 
development in the field led to the discovery of the silencing protein family of Sir2 
and its members (Brachmann et al., 1995).  
Besides their role in transcriptional silencing, yeast sirtuins have also 
been implicated in regulating genomic stability, cell cycle progression, life span 
extension, and oxidative stress (Toiber et al., 2011). Cells lacking Sir2 have a 
reduced replicative life span while cells with additional Sir2 display a much longer 
life span than the control wild type (Sinclair and Guarente, 1997). This lifespan 
extension is a consequence of hypersilencing of the rDNA, which reduces 
recombination and the production of extrachromosomal rDNA circles, a known 
cause of senescence in ageing mother cells (Bitterman et al., 2002).  
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Based on the homology to yeast histone deacetylases, seven mammalian 
homologs of Sir2 (SIRT1 - 7) have been identified and are divided into four 
subclasses based on sub-cellular localization and deacetylase activity. SIRT1, 6, 
and 7 are mostly present in the nucleus; SIRT2 is predominantly cytoplasmic but 
translocates to the nucleus during the cell cycle; and SIRT3, 4, and 5 have been 
characterized as mitochondrial sirtuins (Finkel et al., 2009). Moreover, SIRT 1-3 
have demonstrated robust deacetylase activity, whereas SIRT4 appears to 
function mainly as an ADP-ribosyl transferase (Imai et al., 2000). SIRT6 has both 
ADP-ribosyltransferase and deacetylase activity and SIRT5 has been shown to 
exhibit more demalonylase and desuccinylase activity than that of a deacetylase 
(Imai et al., 2000; Yuan and Marmorstein, 2012).  
A classic sirtuin deacetylation reaction catalyzes the transfer of the acetyl 
group from the acetyl lysine of proteins to NAD+ resulting in 2′-O-acetyl-ADP-
ribose and free nicotinamide (Kaeberlein et al., 1999). Cleavage of the glycosidic 
bond between nicotinamide and ribose of NAD+ during the sirtuin mediated 
deacetylation results in the transfer of an acetyl group on the acetylated lysine 
residue of the target peptide to the ribose moiety of ADP-ribose. The 
nicotinamide by-product is a non-competitive inhibitor of sirtuins and inhibits 
enzyme activity through a base exchange process, resulting in an intermediate β-
NAD+ which blocks further deacetylation (Du et al., 2011; Jackson et al., 2003).  
Several crystallography studies of sirtuin structures have provided deeper 
insight into its molecular mechanisms of substrate specificity, regulation and 
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catalysis. Primary sequence alignment of sirtuins has revealed that they share a 
highly conserved catalytic core with sequentially variant N- and C- terminal 
segments of different lengths. This conserved catalytic core domain contains a 
Rossmann fold domain specific for NAD+ binding, a helical module consisting of 
three to four helices, and a variable small zinc-binding ribbon module 
(Chakrabarty and Balaram, 2010). The Rossmann fold further links the two 
modules, resulting in a hydrophobic cleft formation which serves as the binding 
site for the substrate (preferably a thioacetyllysine peptide) and NAD+ on 
opposite sides thus leading to catalysis (Chakrabarty and Balaram, 2010). The 
zinc ion does not participate in the deacetylation process but plays an integral 
role in maintaining structure. Mutations leading to loss of the zinc have been 
shown to abolish deacetylase activity due to collapses within the structure 
(Levine and Klionsky, 2004).   
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       Adapted from Nogueiras et.al. 2012. APS 10.1152 
Figure 2: Crystal structure of Sir2 with an acetyl-ribosyl-ADP intermediate. The 
zinc binding site is highlighted in cyan and the Rossmann fold like NAD+ binding 
site is highlighted in orange. 
 
SIRT1 is the mammalian ortholog of yeast Sir2. The importance of this 
deacetylase in a growing number of cellular processes resulted in the synthesis 
of selective activators and inhibitors to further dissect its role. Howitz et al. was 
the first to identify SIRT1 activators through a high-throughput screening using a 
commercial fluorescence deacetylation kit (Borra et al., 2005). Resveratrol, a 
polyphenol found in red wine was identified as the most potent activator and was 
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shown to decrease the Km of the substrate and NAD+ with no changes in the Vmax 
of the reaction, suggesting it was an allosteric regulator of SIRT1 (Borra et al., 
2005). However, two independent reports attributed the in vitro effects of 
resveratrol-mediated SIRT1 catalyzed deacetylation as a substrate artifact 
(Kaeberlein et al., 2005; Pacholec et al., 2010). Resveratrol was shown to 
increase the affinity and deacetylation of the fluorophore-peptide with no 
influence on the peptide in the absence of the fluorophore group (Kaeberlein et 
al., 2005; Pacholec et al., 2010). This dispute eventually resulted in the 
conclusion that resveratrol increased SIRT1 activity, though not necessarily 
through direct activation (Pan et al., 2012).  
A study in 2011 looked at truncations in the N- and C- terminal segments 
of SIRT1 to play a role in modulating the deacetylase activity (Hubbard et al., 
2013). It was thus identified that the N-terminus was required for maximum 
catalytic activity while the conserved catalytic core domain demonstrated weak 
activity independently (Hubbard et al., 2013). Furthermore, the C-terminus was 
shown to influence the activity of established sirtuin inhibitors, known to function 
through the catalytic core domain (Hubbard et al., 2013). Despite the ongoing 
debate on the legitimacy of mechanism of action, the pharmacological relevance 
of SIRT1 activation and the mechanism of action of STACs are still of great 
interest. 
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Role of SIRT1 in energy metabolism 
NAD+ dependent SIRT1 activity is important in the regulation of cellular 
and systemic energy homeostasis because it can sense nutrient availability and 
connect cellular energy status to various transcriptional outcomes. Studies 
looking at calorie restriction, fasting, and exercise show increases in cellular 
NAD+ levels in mammalian tissues with a corresponding increase in SIRT1 
deacetylase activity (Guarente, 2007; Houtkooper et al., 2012; Murugesan et al., 
2013). Additionally, activators of AMPK, a major cellular energy sensor, have 
been shown to increase NAD+ levels thereby increasing SIRT1 activity (Cantó et 
al., 2009).  
Once activated, SIRT1 demonstrates affinity towards a broad range of 
histone and non-histone peptide substrates, including transcription factors 
involved in stress response and metabolism pathways (Cantó et al., 2009).  
Prolonged fasting has been shown to increase SIRT1-mediated deacetylation of 
key regulators in gluconeogenesis, fatty acid oxidation and mitochondrial 
biogenesis including forkhead box O-1 (FOXO-1) and peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α), thus increasing their 
transcriptional activity (Brunet et al., 2004; Rodgers et al., 2005). The cyclic 
AMP- responsive element binding protein (CREB) positively induces SIRT1 gene 
transcription during fasting. Conversely, feeding decreases SIRT1 activity via 
increased carbohydrate response element binding protein (ChREBP) 
translocation to the nucleus and binding the SIRT1 promoter, at a site that 
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overlaps CREB binding, thereby repressing gene transcription (Noriega et al., 
2011).  
It has also been demonstrated that pathological conditions such as fatty 
liver in obesity decreases deacetylase activity of SIRT1 (Coste et al., 2008). 
Decreased levels of intracellular NAD+ in fatty livers of obese mice also 
contribute to reduced SIRT1 deacetylase activity (Yoshino et al., 2011). 
Additionally, high fat diet-induced metabolic stress increases the interaction 
between SIRT1 and its endogenous inhibitor, deleted in breast cancer 1 (DBC1), 
resulting in decreased deacetylase activity (Escande et al., 2010). Animal studies 
using STACs have revealed SIRT1 activation to increase mitochondrial content, 
alleviate insulin resistance and improve overall metabolic profiles in a diet-
induced obese model (Baur et al., 2006; Feige et al., 2008; Lagouge et al., 
2006). Mice over-expressing SIRT1 are resistant to weight gain and insulin 
resistance with amelioration in glucose intolerance when fed a high fat diet in 
comparison with wild-type control mice (Pfluger et al., 2008).   
Consistent with these gain-of-function studies, SIRT1 loss-of-function in 
mice results in detrimental metabolic effects. A liver specific SIRT1 knockout 
(SIRT1 LKO) mouse model develops hepatic steatosis with altered fatty acid 
metabolism when fed a high fat diet (Purushotham et al., 2009). SIRT1 LKO mice 
also show impairments in insulin signaling via the mTORC2/Akt pathway, leading 
to oxidative stress, hyperglycemia, and insulin resistance (R.-H. Wang et al., 
2011). Fasting further induces SIRT1 deacetylation and down-regulation of a key 
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lipogenic activator, sterol regulatory element binding protein 1c (SREBP-1c) via 
increased proteosomal degradation and ubiquitination (Ponugoti et al., 2010).  
It has been demonstrated that SIRT1 positively regulates a main 
transcription factor regulating hepatic lipid metabolism, PPAR-α, and hepatocyte-
specific deletion of SIRT1 results in impaired PPAR-α signaling (Purushotham et 
al., 2009). Furthermore, SIRT1 increases the transcriptional activation of PGC-1α 
via deacetylation to increase β-oxidation of fatty acids, leading to lower hepatic 
TAG levels (Purushotham et al., 2009; Rodgers et al., 2008). However, it still 
remains unknown whether SIRT1 deacetylases PPAR-α, despite scientific 
evidence showing SIRT1 regulation of its isoform, PPAR-γ, in the adipose tissue 
(Qiang et al., 2012).  
 
Autophagy: A fasting response similar to lipolysis 
Autophagy is an intracellular lysosomal-mediated degradative pathway 
targeting cytosolic components such as organelles and proteins to be self-
digested thereby maintaining cellular homeostasis. During the autophagic 
process, a single membrane structure surrounds portions of the cytoplasm and 
organelles and fuse to form a double-membrane autophagosome (Howitz et al., 
2003). The outcome of autophagy is the complete dissociation of the substrate 
into its essential components, such as proteins to amino acids and TAG to free 
FAs. The best understood role of autophagy is cellular housekeeping, but in 
addition autophagy participates in processes involved in growth control, cell 
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defense adaption and cell differentiation (Hennig and Neufeld; Meléndez et al., 
2003).  
Three forms of autophagy have been identified in mammalian cells- 
macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA) 
(Howitz et al., 2003). Macro- and microautophagy are similar processes except in 
macroautophagy, the components are sequestered within an autophagosome, 
which fuses with a lysosome to form an autolysosome. In microautophagy, 
sequestration occurs directly within the lysosome. CMA is a chaperone-
dependent selection of cytosolic components that are targeted to the lysosomal 
membrane for degradation (Howitz et al., 2003). Additionally, macroautophagy 
can exist in selective forms within the cell such as mitophagy (resulting in 
mitochondrial turnover) and lipophagy (lipid turnover) to name a few (Czaja et al., 
2013).  
Certain features of the hepatocytes and the liver, such as its regenerative 
capacity, make it an organ dependent on autophagy. Impaired autophagy can 
result in accumulation of toxic products within hepatocytes, thereby increasing 
oxidative stress through damaged organelles and eventually culminating in 
extensive cellular injury (Czaja et al., 2013). Additionally, the liver is an important 
metabolic organ and during nutrient depletion, autophagic degradation within 
hepatocytes recycles cellular components to provide substrates for ATP 
generation (Lum et al., 2005). The above described function of autophagy in the 
liver suggests a mechanism by which autophagy may modulate excessive 
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storage of TAG in NAFLD. Alternatively, aging could promote NAFLD 
development through decreased autophagic capacity of the cell (Czaja et al., 
2013). Despite the tremendous scientific advances exploring the importance of 
hepatic autophagy in cell homeostasis, further investigations are required to 
elucidate the importance of this process in hepatic pathological conditions, 
specifically NAFLD. 
 
Lipophagy: LD specific catabolism via autophagy 
In the recent past, an alternate pathway of lipid degradation has garnered 
attention wherein the cell breaks down lipid via the lysosome (Kaushik and 
Cuervo, 2015; Schroeder et al., 2015). This process is termed lipophagy and it 
serves as a mechanism to regulate intracellular lipid stores and control energy 
homeostasis through breakdown of TAG. In this form of lipid metabolism, TAG in 
LDs is hydrolyzed by acid hydrolases within the lysosome. The primary lipase in 
the lysosome is lysosomal acid lipase (LIPA) which can hydrolyze all three fatty 
acids present in TAG. LIPA is a key enzyme involved in intracellular lipid 
metabolism and FA trafficking and is responsible for the lysosomal hydrolysis of 
TAG into FFAs and cholesterol (Fasano et al., 2012). Deficiency or mutations of 
this enzyme result in rare metabolic storage diseases, namely Wolman’s disease 
(Baratta et al., 2015) and cholesterol ester storage disease (Kuranobu et al., 
2016). The clinical manifestations of this disease include a marked reduction in 
LIPA activity resulting in an accumulation of cholesteryl esters and TAG within 
  21 
the lysosomes in many tissues (Baratta et al., 2015; Kuranobu et al., 2016). 
Infants with Wolman’s disease show growth retardation due to malabsorption, 
hepatomegaly and severe liver dysfunction, making survival beyond one year of 
age rare (Muntoni et al., 2013).  
The consequences of LIPA dysregulation resulting in lipoprotein 
alterations similar to a NAFLD model indicate that both diseases share common 
pathophysiological mechanisms. However very few studies to date have 
assessed LIPA activity in patients with NAFLD and prevalence of the LIPA gene 
mutation is largely unknown. Further research is required to better clarify the 
mechanisms through which modulations in LIPA activity are associated with 
dyslipidemia and liver dysfunction (Baratta et al., 2015; Fasano et al., 2012) 
 
SIRT1 mediated lipophagy 
It has been shown in yeast that withdrawal of nutrients results in the 
formation of autophagosomes with subsequent induction of autophagy (Lum et 
al., 2005; Shintani and Klionsky, 2004). Calorie restriction or nutrient deprival has 
also been shown to induce Sir2 (Jeggo, 1998) and SIRT1, therefore mediating 
the life-extending benefits of the sirtuins (Cohen et al., 2004). In this context, 
several studies have examined the role of SIRT1 in regulating autophagy (Lee et 
al., 2008; McBurney et al., 2013; Shin et al., 2013). SIRT1 also regulates several 
members of the transcription factor Forkhead Box-O (FoxO). Of this family, 
FoxO3 is a major regulator of ubiquitin-mediated proteasomal degradation and is 
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induced by fasting (Sandri et al., 2004). FoxO3 has also been shown to increase 
expression of autophagy-associated proteins such as LC3 and Bnip3 
(Mammucari et al., 2007).   
Recent studies also suggest that autophagy partakes in the process of 
lipid metabolism and this pathway is dependent on SIRT1 (Dong et al., 2013; 
Shibata et al., 2009; Singh et al., 2009). Genetic inhibition of the autophagy-
related gene Atg7 in hepatocytes resulted in an increase in hepatic TAG content 
and lipid droplet accumulation (Singh et al., 2009). Additionally, exogenous lipid 
supplementation increases intracellular trafficking of lipids to the 
autophagosomes as demonstrated through fluorescence measurements and 
electron microscopy experiments (Singh et al., 2009). This increased movement 
of lipids to the autophagosome occurs during nutrient deprivation and this was 
corroborated through enhanced association of lipid droplets and autophagosomal 
protein LC3 during starvation (Singh et al., 2009). Though this mechanism is still 
unclear, it has been suggested that several lipid droplet proteins could mediate 
the interaction with the autophagosome (Czaja et al., 2013). Thus, the rate 
limiting enzyme in TAG hydrolysis, ATGL, and its regulators might be crucial in 
regulating lipophagy in the liver and it would be interesting to further elucidate 
whether SIRT1 mediates this mechanism.  
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SUMMARY 
Ample research has shown that adipose triacylglycerol lipase (ATGL) 
increases the activity of the nuclear receptor peroxisome proliferator-activated 
receptor-α (PPAR-α), a PPAR-γ coactivator-1α (PGC-1α) binding partner, to 
promote fatty acid oxidation.  Since fatty acids bind and activate PPAR-α, it has 
been presumed that fatty acids derived from ATGL-catalyzed lipolysis act as 
PPAR-α ligands. However, our laboratory has shown that administration of 
fenofibrate, a PPAR-α ligand, was unable to rescue PPAR-α target gene 
expression in the absence of ATGL suggesting an alternate mechanism must 
exist.  Sirtuin 1 (SIRT1) is a NAD+ dependent protein deacetylase that regulates 
deacetylation of a host of target proteins including PGC-1α, a transcriptional co-
regulator that binds numerous transcription factors to promote oxidative 
metabolism and mitochondrial biogenesis. Thus, given the importance of SIRT1 
in regulating PGC-1α and subsequently PPAR-α, we investigated if ATGL 
manipulations altered SIRT1 activity as a mechanism to regulate the expression 
of oxidative genes.  We show that SIRT1 deacetylase activity is positively 
regulated by ATGL to promote PGC-1α signaling.  In addition, ATGL mediates 
the effects of β-adrenergic signaling on SIRT1 activity and downstream PGC-
1α/PPAR-α target gene expression. Furthermore, we demonstrate that SIRT1 is 
required for the induction of PGC-1α/PPAR-α target genes and oxidative 
metabolism in response to increased ATGL-mediated lipolysis.  We identify that 
oleate, produced from lipolysis directly activates SIRT1. Taken together, our work 
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identifies a novel signaling axis involving β-adrenergic signaling, ATGL-catalyzed 
oleate and SIRT1 activation that governs transcriptional regulation of oxidative 
metabolism and mitochondrial biogenesis. 
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INTRODUCTION 
SIRT1, first discovered in yeast, is a NAD+ dependent protein deacetylase 
and metabolic regulator that maintains cellular homeostasis through changes in 
energy metabolism. Activated upon calorie restriction or exercise, SIRT1 
deacetylates a host of target proteins to promote oxidative metabolism, stress 
resistance and reduce cellular damage. In response to fasting or exercise 
induced β-adrenergic signaling, the cAMP/protein kinase A (PKA) pathway 
activates SIRT1 to promote downstream oxidative metabolism (Gerhart-Hines et 
al., n.d.). 
 Among the several SIRT1 targets, PGC-1α is a principal target that upon 
deacetylation and activation, binds numerous transcription factors including 
PPAR-α, which is highly expressed in the liver and involved in mitochondrial 
biogenesis and oxidative metabolism. Furthermore, SIRT1 directly binds PPAR-α 
and potentiates PGC-1α/PPAR-α interactions (Purushotham et al., 2009). 
Hepatic specific SIRT1 knockdown is concomitant with increased fat 
accumulation and inflammation (Purushotham et al., 2009; Xu et al., 2010).  
Our laboratory and others have shown that ATGL is a major hepatic lipase 
that increases the activity of PPAR-α and its target genes to promote fatty acid 
oxidation (Ong et al., 2011; Obrowsky et al., 2012; Haemmerle et al., 2011; 
Ahmadian et al., n.d.). Fatty acids bind and activate PPAR-α (Forman et al., 
1997; Kliewer et al., 1994); therefore, it has been presumed that fatty acids 
derived from ATGL-catalyzed lipolysis act as PPAR-α ligands.  However, 
  44 
administration of a PPAR-α agonist to mice with ablated hepatic ATGL was 
unable to normalize oxidative gene expression (Ong et al., 2011), suggesting that 
a more complex mechanism exists that links ATGL to PPAR-α regulation.  Given 
the importance of SIRT1 in regulating PPAR-α (Purushotham et al., 2009), we 
tested if manipulating ATGL alters SIRT1 activity to regulate PPAR-α activity and 
subsequent oxidative metabolism. Herein, we characterize a novel signaling axis 
involving β-adrenergic signaling, ATGL-catalyzed lipolysis, and SIRT1 activation 
that governs hepatic oxidative metabolism.  Further, we show that oleate 
generated specifically by ATGL-catalyzed lipolysis directly activates SIRT1.  
These studies identify for the first time a non-substrate endogenous metabolite 
that positively regulates SIRT1 activity.  
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EXPERIMENTAL METHODS 
SIRT1 fluorometric kinetic assay 
SIRT1 activity was measured with a fluorometric kinetic assay kit (Enzo Life 
Sciences catalogue number: BML-AK555-001) according to the manufacturers 
protocol. For cellular assays using the fluorometric kinetic assays, crude nuclear 
protein was isolated by sucrose gradient centrifugation, and activity was 
normalized to protein content. One U of the recombinant SIRT1 (Enzo Life 
Sciences) was used according to kit protocol with 0.5 mM acetylated fluor 
peptide, and 10 mM NAD+. This enzyme-substrate complex was incubated in the 
presence of activator for 15 minutes and the reaction quenched by the addition of 
a developer II reagent. The developer II was incubated for a further 45 min 
before reading with an excitation wavelength of 360 nm and emission at 460 nm. 
The final mixture was incubated for 45 min before reading the plate (Bio-Tek 
Synnergy HT Microplate Reader) at an excitation wavelength of 360 nm and 
emission at 460 nm.  SIRT1 activity is expressed as percentage change over 
control.  
 
Fatty acid activation assay: 1 mM stocks of different fatty acids were prepared 
in pure EtOH and dried down using a nitrogen evaporator.  Once completely 
dried, the lipids were reconstituted and conjugated with 2.1 mM BSA and the final 
volume was made up using water.  Fluorometric SIRT1 assay was performed as 
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detailed above; the substrate and developer II was prepared as per kit 
instructions. 
 
SIRT1 recycling assay.  
SIRT1 reactions were carried out in a final volume of 200 μL per well in a flat-
bottom clear 96-well plate. Assay mixtures contained different concentrations of 
AcH3 as described in the Figure 2A, 200 μM NAD+, 0.2 mM NAD(P)H, 1 mM 
DTT, 3.3 mM α-ketoglutarate, 2 μM PncA (nicotinamidase), 3 units of glutamate 
dehydrogenase from bovine liver, 1 μM SIRT1 in 20 mM potassium phosphate at 
pH 7.5.  All assay components except SIRT1 or NAD+ were preincubated at 25°C 
for 5 min or until absorbance at 340 nm stabilized and the reaction was initiated 
by addition of SIRT1 or NAD+. The rates were analyzed continuously for 10, 20, 
30, 60, 90 and 120 min by measuring NAD(P)H consumption at 340 nm. Rates 
were determined from the slopes of the initial linear portion of each curve using 
an extinction coefficient for NAD(P)H of 6.22 mM-1 cm-1. The background rates of 
reactions lacking either SIRT1 or NAD+ were subtracted from the initial velocities 
of the SIRT1-catalyzed reactions.  Data is presented as units/min (U/min) and 1 
unit is defined as change in absorbance at 340nm over change in time. 
 
PPAR-α and PGC-1α Reporter Assay 
MEFs were transfected with indicated firefly luciferase reporter plasmids (TK-MH-
UASluc), control Renilla luciferase (pRLSV40), and indicated GAL4-PPAR-α or 
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PGC-1α constructs using Effectene Transfection Reagent (QIAGEN). For PPAR-
α reporter activity, pSG5-GAL4-PPARα-LBD construct was transfected into cells. 
For PGC-1α reporter activity, pCMX-GAL4-PGC1α, provided by Brian Finck 
(Washington University in St. Louis), was transfected into cells. To raise ATGL 
expression, MEFs were transduced with 60 multiplicity of infection Ad-ATGL or 
Ad-GFP for 18 h. To inhibit SIRT1 activity, MEFs were incubated for 18 h with 10 
mmol/L EX-527. Cells were stimulated with 1 mmol/L cAMP analog for 4 h. 
Following treatments with indicated adenovirus or drugs, luciferase activity was 
measured using the Dual-Luciferase Reporter Assay System (Promega). Firefly 
luciferase activity was normalized to the coexpressed Renilla luciferase activity. 
 
RNA Isolation and RT-PCR Analysis 
RNA was extracted with TRIzol from liver tissues followed by reverse 
transcription with SuperScript VILO cDNA Synthesis Kit (Invitrogen) to generate 
cDNA. Gene expression was quantified as described previously (Ong et al., 
2011). 
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RESULTS 
ATGL is required to regulate β-adrenergic induced hepatic SIRT1 activity 
and downstream PGC1-α /PPAR-α signaling 
Since PPAR-α signaling is a major pathway affected by hepatic ablation of 
SIRT1, we sought to examine if SIRT1 plays a role in ATGL-mediated regulation 
of PPAR-α activity. Hepatic SIRT1 activity was suppressed by ~50% in mice 
treated with adenovirus harboring shRNA targeted to ATGL, whereas adenoviral-
mediated overexpression of ATGL increased hepatic SIRT1 activity (Figure 1A). 
SIRT1 mRNA abundance was also reduced in response to ATGL knockdown 
(Figure 1B), and targets of SIRT1, PGC-1α. and FOXO1 (forkhead box protein 
O1), were hyperacetylated in response to ATGL knockdown (data not shown) 
consistent with reduced SIRT1 activity. 
Since β-adrenergic signaling increases lipolysis and SIRT1 activity 
(Murugesan et al., 2013; Rodgers et al., 2005), we next explored the connection 
between ATGL and SIRT1. Pre-treatment of primary mouse hepatocytes with 
bromoenol lactone (BEL), a lipase inhibitor, blocked the ability of a cell-
permeable cAMP analogue (8-Bromoadenosine 3′,5′-cyclic monophosphate) to 
stimulate SIRT1 activity (Figure 1C). Attenuating cAMP/PKA signaling with a 
PKA inhibitor (H89) also blocked SIRT1 activation by cAMP in primary 
hepatocytes (Figure 1D), suggesting that the PKA arm of the β-adrenergic 
signaling cascade is responsible for the observed effects. Consistent with its 
inhibition of SIRT1, BEL also blocked the induction of PGC-1α reporter activity in 
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response to cAMP in mouse embryonic fibroblasts (MEFs) (Figure 1E). Similarly, 
BEL blocked the induction of PPAR-α and PGC-1α and their target genes in 
cultured primary hepatocytes in response to cAMP (data not shown). Taken 
together, these findings demonstrate that ATGL-catalyzed lipolysis is required for 
the cAMP/PKA-mediated activation of SIRT1 and induction of PGC-1α/PPAR-α 
target genes. 
 
Oleate released from ATGL-catalyzed lipolysis activates SIRT1 
Based on the above data showing that ATGL regulates SIRT1 activity, we 
hypothesized that catabolism of triglycerides by ATGL releases specific lipolytic 
products or downstream metabolites that activate SIRT1. Additionally, global and 
liver-specific ATGL knockdown in mice leads to enrichment of oleate in liver 
triglyceride (Eichmann et al., 2012; Ong et al., 2011), suggesting that ATGL 
preferentially hydrolyzes oleate. Furthermore, it has been shown both in vitro and 
in vivo that with its co-activator CGI-58, ATGL shows highest affinity for the 
monounsaturated fatty acids palmitoleic and oleic acid at sn-1 and sn-2 positions 
resulting in sn-1,3 and sn-2, 3 DAG (Eichmann et al., 2012). Using a commercial 
fluorometric kinetic assay with recombinant SIRT1 and a TAMRA fluoro-peptide, 
we found that oleate increased SIRT1 activity in a dose-dependent manner 
(Figure 2A). In contrast, the saturated fatty acid palmitate, and polyunsaturated 
fatty acids eicosapentaenoate (EPA), docosahexaenoate (DHA), and linoleate 
(LA) did not increase SIRT1 activity.  
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We next evaluated SIRT1 enzyme kinetics in response to varying 
concentrations of acetylated histone H3 peptide (AcH3) in the SIRT1 recycling 
assay. These data revealed that oleate lowers the Km for the AcH3 peptide 
substrate approximately 10-fold (Figure 2B). Incubating primary hepatocytes with 
oleate for 60 min induced SIRT1 activity, but inhibition of lipolysis by BEL 
abolished this activation (Figure 2C). These data suggest that the mechanism to 
activate SIRT1 involves a specific pool of oleate that is generated after 
esterification of oleate into triglyceride and its subsequent lipolysis by ATGL. 
 
SIRT1 is required for the effects of ATGL-catalyzed oleate on PGC-
1α/PPAR-α Activity 
To examine the requirement for SIRT1 in mediating the effect of ATGL-
catalyzed lipolysis, we used a luciferase assay system to test PGC-1α/PPAR-α 
reporter activity. Increasing the ratio of oleate to palmitate exposure in MEFs and 
primary mouse hepatocytes synergized with cAMP to induce Gal4-PGC1-α 
activity in agreement with the specificity of oleate on SIRT1 activation (Figure 
3A).   Finally, Gal4-PGC-1α activity was stimulated by both cAMP and ATGL 
overexpression in MEF cells, but this activation was abolished in response to 
chemical inhibition of SIRT1 (Figure 3B) and in SIRT1 knockout MEFs (Figure 
3C).  Taken together, these data demonstrate that SIRT1 is required for ATGL-
mediated induction of oxidative metabolism. 
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Figure 1. ATGL/lipolysis activates SIRT1. (1A&B) SIRT1 activity (relative 
fluorescence units (RLU) normalized to liver nuclear protein lysate) and gene 
expression determined from liver tissues of mice treated with the indicated 
adenovirues for 7 days. (1C) SIRT1 activity of primary hepatocytes treated with 
or without 1 mM cAMP analogue (8-Bromoadenosine 3′,5′-cyclic 
monophosphate) for 10 minutes, after a 1hour pretreatment with 2 μM lipase 
inhibitor, bromoenol lactone (BEL). (1D) SIRT1 activity as determined by 
deacetylase fluorometric assay of primary hepatocyte nuclear lysates.  Cells 
were treated with or without 1mM cAMP analogue for 10 minutes, after a 1 hour 
pre-treatment with 30 μM protein kinase A inhibitor H89.  (1E) Inhibition of ATGL 
blocks cAMP induction of PGC-1α reporter. 
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Figure 2. Oleate activates SIRT1. (2A) Dose-dependent activation of SIRT1 by 
oleate compared with other fatty acids. SIRT1 activity was determined by cycling 
assay with increasing concentrations of oleate, palmitate (PA), 
eicosapentaenoate (EPA), docosahexaenoate (DHA), or linoleate (LA). 
Increased SIRT1 activity with oleate as determined by fluorometric kinetic assay. 
(2B) Oleate decreases SIRT1 Km for AcH3 substrate. (2C) Exogenous oleate 
requires lipolysis to activate SIRT1 in primary mouse hepatocytes.  Primary 
mouse hepatocytes were incubated with the indicated concentration of oleate 
complexed to BSA, or BSA alone (vehicle) for 10, 30 or 60 min, following pre-
incubation with BEL 2 μM BEL for 1 h.  SIRT1 activity was determined from 
nuclear lysates using the fluorometric kinetic assay. 
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Figure 3.  SIRT1 is required for the effects of ATGL on PGC-1α/PPAR-α 
activity. 
(3A) Increasing the proportion of exogenous oleate synergizes with cAMP to 
induce PGC-1α reporter activity.  MEFs were cultured with 400 μM total fatty 
acids differing in the proportion of palmitate and oleate for 16 h and dual 
luciferase reporter activity was subsequently measured.  (3B) Chemical inhibition 
of SIRT1 blocks the effect of cAMP and ATGL on PGC-1α activity.  Wild type 
MEFs were transfected with PGC-1α reporter constructs and transduced with 
indicated adenovirus followed by incubation with 10 μM EX527 for 18 h.  Cells 
were then treated with or without 1mM cAMP analogue for 4 h prior to cell lysis 
and analysis for PGC-1α reporter activity.  (3C) cAMP and ATGL activate PGC-
1α reporter activity in a SIRT1 dependent manner.  Wild type or SIRT1 -/- MEFs 
were transfected with Gal4-PGC-1α reporter constructs, transduced with 
indicated adenovirus, stimulated with cAMP, and reporter activity was 
determined.  
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Figure 4: Summary/Model: The above data shows that β-adrenergic stimulation 
requires ATGL to activate SIRT1 and that oleate derived through ATGL 
hydrolysis, activates SIRT1 and its downstream targets. We have shown that 
oleate is a direct activator of SIRT1, but further studies are required to elucidate 
this mechanism of regulation. 
 
 
  55 
DISCUSSION 
These studies identify a new signaling mechanism whereby an 
endogenously produced metabolite directly regulates SIRT1 activity.  We show 
that only oleate produced exclusively from lipolysis activates SIRT1 suggesting 
that there are inherently different pools of intracellular fatty acids with unique 
signaling properties. Moreover, these data provide a mechanism for the previous 
observation that oleate enhances the SIRT1/ PGC-1α pathway (Lim et al., 2013) 
It is currently unknown how oleate regulates SIRT1.  Recent publications 
have shown that numerous sirtuins, including SIRT1, possess long chain 
deacylase activity (Feldman et al., 2013; Jiang et al., 2013). Moreover, long chain 
fatty acids activate SIRT6 deacetylase activity, but competitively inhibit long 
chain deacylase activity suggesting that fatty acids bind within the SIRT6 
catalytic pocket (Feldman et al., 2013). Thus, it is plausible that oleate binds 
within the catalytic pocket of SIRT1 to promote deacetylase activity.  Additional 
studies are underway to further define the mechanism through which oleate 
facilitates SIRT1 deacetylase activity.  
Numerous studies have linked lipolysis, mediated through manipulations 
of ATGL or other lipid droplet proteins, to changes in PPAR-α and oxidative gene 
expression (Ahmadian et al., n.d.; Haemmerle et al., n.d.; Obrowsky et al., n.d.; 
Ong et al., 2011; Sapiro et al., 2009).  Because fatty acids are ligands for PPAR-
α, it has been presumed that fatty acid generated from lipolysis acts as agonists 
for PPAR-α (Mottillo et al., 2012).  However, we have shown that administration 
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of a PPAR-α agonist, results in a similar fold-induction of PPAR-α target genes in 
livers of mice treated control or ATGL shRNA adenoviruses, but was unable to 
normalize gene expression between the two groups (Ong et al., 2011).  
Consequently, our data shows that ATGL, via oleate, activates SIRT1 and 
provides strong evidence for an alternate signaling mechanism linking lipolysis to 
PPAR-α activity.  Consistent with our findings, administration of a PPAR-α 
agonist (fenofibrate) was also unable to normalize PPAR-α target gene 
expression in fasted mice with ablated hepatic SIRT1 (Purushotham et al., 2009).   
The discovery that resveratrol a polyphenol in red wine activates SIRT1 
was thought to be the one of the several hypotheses that explain the low rates of 
cardiovascular disease and potential beneficial effects on the metabolic 
syndrome with the Mediterranean Diet (Amiot et al., 2016).  However, this 
enthusiasm has been tempered by the observation that supraphysiological doses 
of resveratrol are required to elicit its effects and by data showing that the effects 
of resveratrol on SIRT1 are indirect and non-specific (Borra et al., 2005; 
Kaeberlein et al., 2005; Pacholec et al., 2010). Novel activators as well various 
methods to manipulate NAD+ metabolism have since emerged as alternatives to 
increase SIRT1 activity and to recapitulate the effects of resveratrol (Baur, 2010). 
However, it remains unclear if the Mediterranean Diet activates SIRT1 
independent of resveratrol.  Olive oil and nuts, both high in the monounsaturated 
fatty acid (MUFA) oleate, are also major constituents of the Mediterranean Diet.  
The current study shows that ATGL-mediated hydrolysis of oleate is required for 
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the effects of β-adrenergic signaling on SIRT1 activity. These data suggest that 
factors contributing to β-adrenergic signaling such as fasting, caloric restriction or 
exercise are required for oleate-mediated activation of SIRT1.  Thus, we 
speculate that the above-defined regulation of SIRT1 may be an important 
mechanism explaining the health benefits of the Mediterranean Lifestyle, namely 
adherence to the Mediterranean Diet and abundant physical activity.  Ongoing 
studies to define the mechanism through which oleate activates SIRT1 and 
factors that regulate ATGL and selectivity towards oleate hydrolysis may provide 
novel avenues to activate SIRT1 to prevent or treat metabolic diseases and 
regulate lifespan.   
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SUMMARY 
Hepatic lipid droplet (LD) catabolism is thought to occur via cytosolic 
lipases such as adipose triglyceride lipase (ATGL) or through autophagy of LDs, 
a process known as lipophagy. We tested the potential interplay between these 
metabolic processes and its effects on hepatic lipid metabolism. We showed that 
hepatic ATGL was both necessary and sufficient to induce autophagy and 
lipophagy. Following previous work showing that ATGL promotes sirtuin 1 
(SIRT1) activity, studies in liver-specific SIRT1-/- mice and in primary hepatocytes 
revealed that SIRT1 was required for ATGL-mediated induction of autophagy and 
lipophagy. Moreover, lipophagy was required for ATGL to promote LD 
catabolism.  ATGL promoted lysosomal-mediated efflux of FAs from hepatocytes, 
which occurs prior to their reuptake and utilization in β-oxidation or 
reesterification pathways. Taken together, these studies show that ATGL-
mediated signaling promotes autophagy/lipophagy to control hepatic LD 
catabolism and FA efflux. 
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INTRODUCTION 
The LD is the major storage organelle of intracellular triacylglycerol (TAG) 
and, therefore, is the defining characteristic of non-alcoholic fatty liver disease.  
Historically thought to be inert energy storage depots, LDs are increasingly 
recognized as dynamic organelles involved in many cellular processes beyond 
energy storage (Greenberg et al., 2011). Despite significant advances into our 
understanding of LD catabolism in adipose tissue, there is relatively limited 
knowledge on the regulation and role of hepatic lipolysis.  Studies conducted by 
our laboratory and others have identified ATGL as a major hepatic lipase that 
regulates TAG turnover.  Specifically, shRNA knockdown or genetic ablation of 
hepatic ATGL promotes steatosis (Ong et al., 2011; Wu et al., 2012), whereas 
overexpression of ATGL in the liver alleviates steatosis (Turpin et al., 2011). 
Numerous studies show that ATGL specifically channels hydrolyzed fatty acids 
(FAs) to oxidative pathways and does not influence VLDL secretion (Ong et al., 
2011; Wu et al., 2012).  Additionally, hepatic ATGL promotes SIRT1 activity to 
control PPAR-α/PGC-1α signaling and oxidative metabolism (Khan, et al., 2015). 
Thus, in addition to its prominent roles in tissues such as adipose and heart, 
ATGL also appears to play a critical role in regulating hepatic energy metabolism 
and signaling.  
Autophagy is a cellular recycling mechanism that provides cells with a 
source of energy during starvation (He and Klionsky, 2009). Autophagy can be 
classified into three categories based on lysosomal cargo delivery: 
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macroautophagy (He and Klionsky, 2009), chaperone-mediated autophagy 
(Cuervo and Wong, 2014) and microautophagy (Santambrogio and Cuervo, 
2011).  The role of autophagy in TAG hydrolysis was unclear until Singh et al. 
showed that inhibiting autophagy promoted LD accumulation and attenuated 
oxidation of the hydrolyzed FAs (Singh et al., 2009). Since these findings of 
autophagy-mediated lipid mobilization, termed lipophagy, a plethora of studies 
have shown the existence of lipophagy in diverse cell types such as 
macrophages (Ouimet et al., 2011), neurons (Kaushik et al., 2011) and 
lymphocytes (Hubbard et al., 2010). Less is known in the liver, although recent 
studies have provided some mechanistic insights into lipophagy.  Schroeder et 
al. identified the small GTPase Rab7 as a key regulator of lipophagy to control 
hepatic LD degradation (Schroeder et al., 2015).  Chaperone-mediated 
autophagy has also been shown to contribute to hepatic LD catabolism via its 
degradation of the LD proteins Perilipin 2 and Perilipin 3 to increase association 
between ATGL and LDs and enhance lipolysis (Kaushik and Cuervo, 2015).  
Given the above information, we decided to further investigate the link between 
hepatic ATGL-mediated TAG hydrolysis and autophagy/lipophagy. Herein, we 
demonstrate that hepatic ATGL promotes LD catabolism and FA oxidation via 
SIRT1-mediated induction of lipophagy and FA efflux.  
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EXPERIMENTAL PROCEDURES 
Animals, diets and adenovirus administration 
All animal protocols were approved by the University of Minnesota 
Institutional Animal Care and Use Committee or the Austrian Federal Ministry of 
Science and Research, Division of Genetic Engineering and Animal Experiments, 
Vienna, Austria.  Eight to ten week old C57/Bl6 male mice were housed and 
acclimatized as previously described (Ong et al. 2011). Adenoviruses to 
manipulate ATGL and SIRT1 expression were provided by Andrew Greenberg 
and X.C. Dong respectively, and administered via the tail vein as previously 
described (Khan, et al., 2015). All mice had free access to water and were fed a 
purified control diet (TD 94045; Harlan Teklad Premier Laboratory), after 
adenoviral administration. One week following adenovirus injection, the mice 
were sacrificed for liver tissue and serum collection after a 16 hour overnight fast 
(shATGL treatment) or a 4 hour fast (Ad-ATGL treatment). Homozygous SIRT1 
floxed mice were purchased from JAX Labs and were cross-bred to Alb-Cre 
transgenic mice to generate liver specific SIRT1-/- mice.  Wild type and LIPA-/- 
mice (Du et al., 2001a) were maintained in a clean environment with unlimited 
access to chow diet (4% fat and 19% protein; Altromin 1324, Lage, Germany) 
and water in a regular light-dark cycle (12 hour light, 12 hour dark).  
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RNA isolation, quantitative real-time PCR analysis   
RNA was extracted with Trizol from liver tissues followed by reverse-
transcription with SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen) to 
generate cDNA. Gene expression was quantified as described previously (Khan, 
et al., 2015).  
Cell culture, adenoviral infection and radiolabeling 
Hepatocytes were isolated as described previously (Ong et al. 2011) and 
were transduced with adenovirus expressing ATGL or a control null vector virus 4 
hours after plating.  Experiments measuring lipid incorporation (pulse) to 
measure TAG turnover or media FA efflux were performed in M199 media 
(Invitrogen) containing 26 mmol/L sodium bicarbonate, 23 mmol/L HEPES, 50 
IU/ml penicillin, 50 μg/ml streptomycin, 100 nmol/L dexamethasone, 11 mmol/L 
glucose and 100 nmol/L insulin. The following morning the cells were pulsed with 
500 µM [1-14C]oleate added to the above media for 2 hours. Some cells were 
harvested at the end of the pulse period to measure radiolabel incorporation into 
cellular lipid fractions. The remainder cells were washed with PBS and media 
were replaced with fresh complete M199 (as described above) lacking insulin for 
an additional 6-8 hours (chase period) followed by collection of media and cells 
for lipid extraction.  FAs oxidized or effluxed during the chase period are 
expressed as a percentage of the pulse [14C]TAG.  All experiments to determine 
autophagy induction in hepatocytes were performed in complete M199 without 
hormones unless specified otherwise. Media FAs were extracted using the Dole 
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extraction method using Dole reagent, hexane and water in a (5:3:2) ratio (Dole 
1956). Lipid samples were separated into different fractions by thin layer 
chromatography (TLC) and analyzed as described previously (Ong et al., 2014). 
Transwell studies were performed using a transwell insert with a microporous 
membrane (Corning™ Costar™ Transwell™ Permeable Supports). “Donor” cells 
were plated in the transwell (apical portion) and transduced with the specified 
adenoviruses, followed by an overnight pulse with C-12 BODIPY FA 558/68 
(Invitrogen). The following day transwells containing the donor cells were 
transferred onto wells containing “acceptor” cells plated in the basal portion and 
FA efflux was monitored after a 4 hour chase period.   
Western Blotting  
Protein extraction and immunoblotting were performed as described 
previously (Khan, et al., 2015). LAMP1 and LIPA antibodies were obtained from 
ABCAM (Cat. No’s: ab24170 and ab36597 respectively). LC3 and ATG5 
antibodies were purchased from Novus Biologicals (Cat. No’s: NB100-2220 and 
NB110-53818 respectively). SIRT1, ATGL and p62 antibodies were purchased 
from Cell Signaling Technology (Cat. No’s: 8469S, 2439S and 5114S 
respectively). Beta-Actin antibody was obtained from Bio-Rad (Cat. No: 
MCA5775GA). 
Chemical reagents/Vectors 
Lipase inhibitor ATGListatin was purchased from Xcess Biosciences (Cat. 
No: MC0150-2s) and used in cells at 30 µM concentration in DMSO for 2 hours 
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(for imaging studies) and up to 8 hours for pulse-chase experiments. Chloroquine 
was purchased from Sigma-Aldrich (Cat. No: c6628) and Vacuolin1 from Santa 
Cruz (Cat. No: 351985-151). CB16.2 and LAListat were kind donations from Dr. 
Concetta DiRusso (University of Nebraksa) and Dr. Paul Helquist (Notre Dame 
University) respectively. All autophagy inhibitors were used at the specified 
concentrations for the duration of the chase.  The dual reporter plasmid RFP-
GFP-LC3 was a kind donation from Dr. Mark McNiven (Mayo Clinic) and was 
transfected at 250 ng/well.  siATG5 was custom synthesized from Qiagen and 
siLIPA was procured from Sigma-Aldrich (Cat. No: EMU075891). All vectors 
were administered using Qiagen’s Effectene Transfection Reagent.  
Confocal imaging 
For immunofluorescence microscopy, cells were grown on coverslips and 
fixed with 4% paraformaldehyde for 30 minutes and blocked with 1% BSA, 10% 
donkey serum in phosphate buffer saline (PBS). Incubation with primary 
(overnight at 4°C) and secondary (1 hour at RT) antibodies was done in the 
above-mentioned blocking buffer. The secondary antibody conjugated to Alexa 
Fluor 488 or Fluor 567 was purchased from Invitrogen. For LD staining, cells 
were incubated with LipidTOX™ Deep Red or Green Neutral Lipid Stain (1 µM; 
Invitrogen) for 30 minutes at 37°C after fixation. For lysosomal staining, cells 
were incubated with 20 nM Lysotracker Red DND-99 (Invitrogen) for 30 minutes 
at 37°C before fixation. Nuclei were stained with DAPI (4′, 6-diamidino-2-
phenylindole) for 10 minutes followed by mounting onto slides for visualization.  
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All images were acquired with a Nikon Olympus 200 fluorescence microscope 
(Carl Zeiss Microscopy) with a 60X oil objective and 0.6 numerical aperture, and 
prepared using ImageJ (NIH).  Images from 5 different fields per well were 
captured, and experiments were performed in triplicate.  
For imaging tissues, paraffin blocks were generated from formaldehyde 
fixed livers. Slides from these blocks were de-paraffinized using xylene and 
ethanol washes alternatively. This was followed by an antigen retrieval step 
which included boiling the slides in 10 mM sodium citrate buffer with 0.5% 
Tween-20 and subsequently permeabilization in a buffer containing 0.2% Triton 
X-100 in PBS. Finally the slides were blocked using 10% donkey serum in 1% 
BSA for 1 hour at room temperature followed by overnight incubation with 
primary antibody at a dilution of 1:100. The following day, slides were washed 
and incubated with fluorophore-conjugated secondary antibodies at 1:100 dilution 
for 1 hour at room temperature, followed by addition of DAPI and subsequent 
mounting with coverslips.  
LC-MS analysis of hepatic lipids 
Hepatic lipids were extracted from the liver based on previous methods 
(Bligh and Dyer, 1959). Liver samples (100 mg) were homogenized in 0.5 ml 
methanol and mixed with 0.5 ml chloroform and 0.4 ml water. Phase separation 
was achieved by 10 minute centrifugation at 18,000 g. The lipid fraction in the 
chloroform phase was dried under nitrogen and then reconstituted in 0.5 ml n-
butanol. A 5 µL aliquot of diluted serum or liver lipid sample was injected into an 
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AcquityTM UPLC system (Waters, Milford, MA) and separated by a gradient of 
mobile phase ranging from water to 95% aqueous acetonitrile containing 0.1% 
formic acid over a 10-min run. LC eluents were introduced into a Xevo-G2-S 
mass spectrometer (Waters) for accurate mass measurement and ion counting. 
Capillary voltage and cone voltage for electrospray ionization was maintained at 
3 kV and 30 V for positive-mode detection, or at -3 kV and -35 V for negative-
mode detection, respectively. Source temperature and desolvation temperature 
were set at 120 °C and 350 °C, respectively. Nitrogen was used as both cone 
gas (50 L/h) and desolvation gas (600 L/h), and argon as collision gas.  For 
accurate mass measurement, the mass spectrometer was calibrated with sodium 
formate solution (range m/z 50-1000) and monitored by the intermittent injection 
of the lock mass leucine enkephalin ([M+H]+ = 556.2771 m/z and ([M+H]- = 
554.2615 m/z) in real time. Mass chromatograms and mass spectral data were 
acquired and processed by MassLynxTM software (Waters) in centroided format. 
Additional structural information was obtained tandem MS fragmentation with 
collision energies ranging from 15 to 30 eV. 
Statistical Analysis 
Statistical comparisons were made using analysis of variance or student t-
test. All data are presented as means ± SEM and statistical significance was 
declared at P<0.05.  
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RESULTS 
Hepatic ATGL regulates autophagy/lipophagy 
We have previously shown that hepatic ATGL plays an important role in 
TAG turnover and the subsequent channeling of hydrolyzed FAs to oxidative 
pathways as well as upregulating PPAR-α/PGC-1α signaling to control oxidative 
metabolism (Ong et al., 2011). Recent evidence indicates that ATGL exhibits 
multiple LC3-interacting region motifs (LIRs), which are required for LD 
catabolism (Martinez-Lopez et al., 2016). Given that lipophagy also contributes to 
hepatic LD catabolism (Schroeder et al., 2015; Settembre et al., 2013; Singh et 
al., 2009), we sought to dissect the links between hepatic ATGL-catalyzed 
lipolysis and autophagy/lipophagy. Inhibition of ATGL via shRNA-mediated 
knockdown, as previously reported (Ong et al., 2014), or chemical inhibition via 
ATGListatin in liver or primary hepatocytes, respectively, significantly lowered the 
expression of autophagy genes (Figures 1A-B). ATGL knockdown decreased 
hepatic protein levels of LC3II and LAMP1, but increased p62 when compared to 
the scrambled controls (Figures 1C and 7A) consistent with reduced autophagy. 
ATGListatin also reduced LC3 punctae formation in starved MEFs (Figures 1D 
and 7B). To measure autophagic flux, we used the tandem GFP-RFP-LC3 
sensor (Kimura et al. 2007), which contains an acid-labile GFP and acid-resistant 
RFP to distinguish  between autophagosome and autolysosome localization.  We 
observed increased RFP signal relative to GFP in the controls, which was 
abrogated in response to chemical inhibition of ATGL indicating, reduced 
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autophagic flux (Figure 1E).  ATGL knockdown in mouse livers also reduced LC3 
staining and its colocalization with LDs indicating reduced macrolipophagy 
(Figure 1F).  Similarly, ATGListatin reduced localization of lysosomes with LDs in 
primary hepatocytes suggesting suppressed microlipophagy (Figures 1G and 
7C).  
In contrast to ATGL knockdown or inhibition, the livers of Ad-ATGL treated 
mice described in (Ong et al., 2011) had increased expression of autophagy 
genes along with elevated LAMP1 and LC3II and reduced p62 protein levels 
(Figures 2A-B and Figure 7D). ATGL overexpression increased colocalization of 
LDs with LC3 and lysosomes suggesting increased macro- and microlipophagy 
(Figures 2C-D). ATGL overexpression also enhanced autophagic flux in 
hepatocytes transfected with the dual sensor plasmid compared to the control 
(Figure 2E). Thus, these results show that ATGL is a positive regulator of both 
autophagy and lipophagy in the liver. 
 
SIRT1 mediates the effects of ATGL on autophagy induction  
We have shown that hepatic ATGL regulates mitochondrial biogenesis 
and the expression of genes involved in β-oxidation through its regulation of 
SIRT1 (Khan, et al., 2015). Additionally, SIRT1 is a well-established activator of 
autophagy through its deacetylation and activation of key components of the 
autophagy induction network such as the ATG protein family (Lee et al., 2008) 
and transcriptional regulators including PGC-1α, FoxO1, CREB, PPAR-α, 
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ChREBP and FXR (Brunet et al., 2004; Kemper et al., 2009; Qiang et al., 2011; 
Rodgers et al., 2005; Wang et al., 2010). An alternate transcription factor TFEB 
has also been shown to control cellular lipid metabolism in a starvation-
autophagy dependent manner (Settembre et al., 2013) and downstream 
regulation of the transcriptional levels of LAMP1 and lysosomal exocytosis 
(Medina et al., 2011). To examine the importance of SIRT1 in mediating the 
effects of ATGL on hepatic autophagy, we transduced liver-specific SIRT1-/- mice 
(L-SIRT1-/-) with an adenovirus harboring ATGL. Consistent with data from Figure 
2A, Ad-ATGL increased gene expression of several autophagy targets, but this 
effect was abolished in the absence of SIRT1 (Figure 3A). Western blot analysis 
revealed increased expression of LAMP1, ATG5 and LC3II with ATGL 
overexpression in L-SIRTflox/flox mice, but this effect was completely lost in the 
absence of hepatic SIRT1 (Figure 3B). To support our findings from the L-SIRT1-
/- mouse data, we also used a dual adenovirus system to simultaneously 
overexpress ATGL and knockdown SIRT1 (shSIRT1) in the liver (Khan, et al., 
2015) to more acutely regulate SIRT1. Ad-ATGL treated livers had increased 
expression of autophagy genes, which was completely abolished when SIRT1 
was knocked down (Figure 8A). Similarly, ATGL overexpression increased 
LAMP1 protein levels, which required SIRT1 (Figure 8B). In addition, SIRT1 
ablation abrogated the induction of TAG turnover and oxidation of hydrolyzed FA 
oxidation in response to ATGL expression in primary hepatocytes (Figures 3C-D 
and Figure 8C). L-SIRT1-/- mice also had lower ketone body production 
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compared to the floxed controls in response to ATGL expression (Figure 3E). Ad-
ATGL enhanced LC3 colocalization with LDs in primary hepatocytes, which was 
reduced when cells were treated with the SIRT1 inhibitor EX527 (Figure 3F). 
Similar results were observed in the interaction between lysosomes and LDs 
(Figures 3G and 8D). Finally, the increase in autophagic flux in response to Ad-
ATGL was negated by EX527 treatment (Figure 8E). Taken together, these data 
show that SIRT1 mediates the effects of ATGL on promoting 
autophagy/lipophagy. 
Lipophagy mediates the effects of ATGL on TAG catabolism and FA 
oxidation 
Since ATGL promotes lipophagy, we next explored if lipophagy was 
responsible for mediating the effects of ATGL on TAG catabolism and the 
subsequent oxidation of hydrolyzed FAs. Consistent with previous studies (Ong 
et al., 2011; Sapiro et al., 2009), overexpressing ATGL decreased TAG stores, 
but this effect was partially or completely abrogated when autophagy was blunted 
via exposure of hepatocytes to the autophagy inhibitor chloroquine or knockdown 
of ATG5 (Figures 4A-B). Moreover, blocking lipophagy specifically, via the 
lysosomal acid lipase (LIPA) inhibitor Lalistat (Pearson et al., 2014), prevented 
the increase in TAG turnover in response to ATGL overexpression (Figure 4C).  
We have previously shown that ATGL channels hydrolyzed FAs to the 
mitochondria for β-oxidation (Ong et al., 2011), thus, we further tested if 
autophagy/lipophagy was required for this effect.  Similar to the TAG turnover 
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data, blocking autophagy or lipophagy attenuated the oxidation of hydrolyzed 
FAs following ATGL overexpression (Figures 4D-F). Consistent with the above 
results, over-expressing ATGL reduced total lipid stores in hepatocytes and this 
effect was abrogated when autophagy/lipophagy was blocked (Figure 4G).  
Finally, we analyzed livers from whole body LIPA-/- mice that were injected with 
control or ATGL expression adenoviruses. ATGL overexpression was confirmed 
through enhanced protein expression (Figure 9A) and increased TAG hydrolase 
activity (Figure 9B).  Histological analysis revealed pronounced hepatomegaly, 
steatosis and foam cell nests in LIPA-/- mice (Figure 4H) as previously reported 
(Du et al., 2001b), however, ATGL overexpression did not influence liver 
histology and was unable to reduce TAG stores or increase serum ketone 
bodies, as previously seen in wild type mice (Ong et al., 2014; Turpin et al., 
2011), in the absence of LIPA (Figures 4I-K). Thus, these data show that 
lipophagy mediates the effects of ATGL on LD catabolism and the subsequent 
oxidation of liberated FAs.  
 
Hepatic ATGL promotes FA efflux from cells via the lysosome  
We have shown that FA binding proteins including L-FABP, the major liver 
FABP, are not required for the effects of ATGL on oxidation of hydrolyzed FAs 
(Ong et al., 2014), suggesting that an alternate route exists to transport 
hydrolyzed FAs to the mitochondria for oxidation. Since lysosomes can fuse with 
the plasma membrane to release their luminal contents extracellularly (Samie 
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and Xu, 2014), we next explored if FAs generated from lipophagy were effluxed.  
The addition of 2% BSA to the chase media to bind and sequester FAs resulted 
in a robust increase in FA efflux, and the increase in FA efflux in ATGL 
overexpressing cells required the presence of BSA (Figure 5A).  Similarly, ATGL 
knockdown reduced FA efflux by almost 90% (Figure 5B).  Transwell studies 
revealed that ATGL overexpression in donor hepatocytes increased the transfer 
and accumulation of C12 BODIPY in acceptor hepatocytes (Figure 5C).  Since 
BSA only binds FAs to slow, but not prevent, their uptake, we used a chemical 
inhibitor of FA uptake, CB16.2, (Sandoval et al., 2010) as an additional approach 
to measure efflux.  Addition of CB16.2 during the chase period resulted in a 
nearly 15-fold increase in FA efflux in control hepatocytes and further increased 
extracellular FAs in response to ATGL overexpression (Figure 5D). Next, we 
investigated if ATGL-mediated FA efflux was lipophagy-dependent.  The addition 
of Lalistat or chloroquine or knockdown of LIPA (Figure 9C) significantly 
attenuated FA efflux in response to ATGL overexpression (Figures 5E-G).  
Adding an alternate lysosomal turnover inhibitor, Vacuolin1, which prevents the 
Ca2+-dependent fusion of the lysosomes to the cell membrane (Cerny et al., 
2004), blocked the effects of ATGL overexpression on FA efflux (Figure 5H).  
Addition of Vacuolin 1 in transwell studies prevented the transfer and 
accumulation of FAs in acceptor cells co-cultured with hepatocytes 
overexpressing ATGL (Figure 9D).  Vacuolin 1 caused ballooning of lysosomes 
and nearly all LDs were found within lysosomes (Figures 5I) or interacting with 
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lysosomes (Figure 9E), thus, highlighting the importance of lysosomal turnover in 
LD catabolism. Addition of a FABP inhibitor, HTS01307, showed no difference in 
effluxed FAs, thus, further suggesting that cytosolic shuttling of hydrolyzed FAs 
does not contribute to FA efflux (Figure 9F).  
We proceeded to characterize FA efflux using in situ perfused livers from 
mice fed or fasted for 16 hours. Under all conditions tested, overnight fasted mice 
had increased FA efflux compared to fed mice (Figure 5J). As observed in the in 
vitro models, FA efflux was increased by the addition of BSA and further 
increased in the presence of CB16.2. Finally, addition of vacuolin 1 significantly 
blocked FAs released from the liver. 
Next we performed lipidomic analysis on liver samples isolated from 
control and shATGL adenovirus administered mice.  Significantly higher levels of 
sphingomyelin species were found in samples from mice treated with ATGL 
shRNA (Figures 10A-B). Sphingomyelins are converted to ceramides by both 
lysosomal and Golgi-specific sphingomyelinases (SMPD1/SMPD2) (Kolesnick, 
2002).  Correspondingly, the gene expression of SMPD1 and SMPD2 was 
significantly lower in the shATGL samples compared to the control (Figure 10C). 
Sphingomyelins are known to be negative regulators of lysosomal Ca2+ channel 
protein transient receptor potential cation channel mucolipin, subfamily member 1 
(TRPML1) (Shen et al., 2012). TRPML1 channels are involved in lysosomal 
trafficking and expulsion of lysosomal contents, and its dysfunction results in 
several lysosomal storage disorders such as Niemann-Pick Disease Type A and 
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C (NP-A and C) (Lloyd-Evans and Platt, 2011; Soyombo et al., 2006; Wang et 
al., 2015).  We used a TRPML1 agonist (MLSA1) to induce lysosomal Ca2+ leak 
and found more effluxed FAs (Figure 10D).  Concomitantly, cells treated with 
sphingomyelins had lower FA efflux compared to the controls.  Taken together, 
these data indicate that ATGL promotes FA efflux via lysosome fusion to the 
plasma membrane.  
 
ATGL-mediated FA efflux requires reuptake to be channeled towards 
oxidation or TAG synthesis 
FAs liberated from TAG stored in LDs are thought to be either reesterfied 
or used in downstream metabolic pathways including FA oxidation.  Our findings 
indicate that hydrolyzed FAs are effluxed and undergo reuptake prior to further 
metabolism.  To further interrogate this potential pathway, we quantified the 
metabolism of FAs in response to manipulations of FA efflux. As expected, using 
Vacuolin 1 to inhibit FA efflux significantly attenuated the loss of [14C]TAG and 
the oxidation of hydrolyzed FAs in response to ATGL overexpression (Figures 
6A-B). The addition of BSA in the chase media to sequester expelled FAs was 
sufficient to lower cellular [14C]TAG levels in both Ad-Null and Ad-ATGL treated 
hepatocytes and attenuated the increase in oxidation in cells overexpressing 
ATGL (Figures 6C-D).  Similarly, inhibition of FA uptake with CB16.2 lowered 
cellular [14C]TAG in both treatment groups and blocked the induction of FA 
oxidation in ATGL overexpressing cells (Figures 6E-F).  We next labeled cells 
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with [3H]glycerol during the chase period to directly determine if rates of TAG 
synthesis were altered in response to BSA and CB16.2.  Ad-ATGL increased the 
[3H]glycerol incorporation into TAG consistent with more FAs being available as 
substrates for de novo TAG synthesis (Figure 6G).  However, BSA alone or in 
addition to CB16.2 reduced de novo TAG synthesis and abrogated the increase 
in TAG synthesis in response to ATGL overexpression.  Additionally, ATGListatin 
or LAListat had minor effects on reducing FA oxidation in cells treated with 
CB16.2 further highlighting the significance of efflux prior to oxidation (Figure 
6H). Finally, we measured β-hydroxybutyrate in the liver perfusates of the fed 
and fasted mice treated with BSA, CB16.2 and vacuolin 1 described in Figure 5J. 
Although β-hydroxybutyrate did not reach statistical significance in the fasted 
mice, sequestering effluxed FAs (BSA and CB16.2) or preventing lysosome-
mediated efflux (vacuolin 1) significantly reduced hepatic FA oxidation (Figure 
6I). Taken together, these data strongly support a model where ATGL promotes 
FA efflux, which occurs prior to FA reuptake and subsequent oxidation or 
resterification in TAG. 
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Figure 1. Liver-specific inhibition of ATGL attenuates autophagy/lipophagy. 
(A) In vivo ablation of hepatic ATGL via an ATGL shRNA adenovirus reduced 
the expression of autophagy genes (n=5); *P<0.05 vs. control shRNA. (B) 
Inhibition of ATGL in primary hepatocytes with ATGListatin (Astat, 30μM for 36 
hours) decreased autophagy gene expression (n=5); *P<0.05 vs. DMSO. (C) In 
vivo ATGL knockdown reduces the LC3II/LC3I ratio and protein levels of LAMP1, 
and increased p62 expression; a representative western blot and densitometry 
from 3 mice is shown. (D) Astat decreased LC3 puncta in mouse embryonic 
fibroblasts (MEFs) (n=3). € Hepatocytes transfected with the dual RFP-GFP-LC3 
plasmid were treated with Astat to acutely inhibit ATGL. Increased red punctae is 
indicative of enhanced lysosomal activity as observed with the DMSO treatment 
when compared to the Astat treated cells (n=4). (F) Confocal imaging of liver 
sections show reduced LD localizatiob (as measured with the LD protein perilipin 
2, PLIN2) with LC3 in response to ATGL knockdown. (G) Astat decreased 
lysosomal association with LDs in primary mouse hepatocytes (n=3 for F and G). 
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Figure 2. ATGL overexpression is sufficient to promote 
autophagy/lipophagy. 
 (A) In vivo overexpression of hepatic ATGL increased autophagy target gene 
expression (n=5); *P<0.05 vs. Ad-Null. (B) Hepatic ATGL overexpression 
increased the LC3II/LC3I ratio and LAMP1 protein levels as analyzed via western 
blotting. Livers overexpressing ATGL had no visible bands for p62 indicative of 
enhanced autophagosome clearance; a representative Western blot from 3 mice 
is shown. (C-D) In vivo overexpression of hepatic ATGL increased LC3 and 
lysosomal co-localization with LDs stained with PLIN2 or lipidtox. (E) The dual 
reporter RFP-GFP-LC3 was transfected in primary hepatocytes that were 
transduced with Ad-Null or Ad-ATGL adenoviruses; (n=3 for C-E). 
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Figure 3. SIRT1 mediates the effects of ATGL on autophagy/lipophagy.  
(A) The ATGL-mediated increase in autophagy gene expression was 
abolished in the absence of SIRT1. SIRT1flox/flox or L-SIRT1-/- were treated with 
Ad-Null or Ad-ATGL viruses for 7 days prior to sacrifice (n=6); *P<0.05 vs. Ad-
Null and #P<0.05 vs. SIRT1+/+.  (B) Protein expression of autophagy genes in 
response to ATGL overexpression and/or SIRT1 ablation; a representative 
western blot and densitometry analysis from 3 mice is shown. (C-D) Primary 
mouse hepatocytes were treated with dual adenoviruses and TAG turnover and 
FA oxidation during the chase period were measured (n=5); *P<0.05 vs. Ad-Null 
and #P<0.05 vs. shSCR. (E) L-SIRT1-/- mice treated with Ad-ATGL had lower β-
hydroxybutyrate compared to the floxed controls (n=6); *P<0.05 vs. Ad-Null and 
#P<0.05 vs. SIRT1+/+. (F-G) Confocal imaging revealed that Ad-ATGL enhanced 
LC3-LD and lysosome-LD colocalization, which was lost with 10mM EX527, a 
SIRt1 inhibitor (n=2).   
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Figure 4. Lipophagy is required for ATGL-mediated effects on TAG 
catabolism. 
Isolated primary mouse hepatocytes were transduced with Ad-Null or Ad-ATGL 
adenoviruses and treated with 600 μM chloroquine (A), siATG5 (B), 10 μM 
LAListat (C) or their respective controls. Ad-ATGL increased TAG turnover, 
which was abolished with inhibition of autophagy/lipophagy. (D-F) 
Autophagy/lipophagy inhibitors impaired the ATGL-mediated induction in FA 
oxidation (n=6 for A-F); *P<0.05 vs. Ad-Null and #P<0.05 vs. siCtrl or vehicle. (G) 
Chloroquine and LAListat, added during the chase resulted in increased LD 
staining and blocked LD depletion in response to ATGL overexpression. Primary 
mouse hepatocytes were pulsed with a C-12 BODIPY FA (558/68) overnight, 
followed by an 8 hour chase in insulin free M199 along with inhibitors (n=3). (H) 
H&E staining of liver sections from LIPA-/- treated with Ad-Null or Ad-ATGL 
adenoviruses. ATGL overexpression did not influence liver weights (I), liver TAG 
(J) or serum ketone bodies (K) in LIPA-/- mice (n=6). 
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Figure 5. ATGL mediates FA release from cells via the lysosome. (A-B) 
Pulse-chase experiments show that hepatocytes transduced with Ad-ATGL 
increased and with Ad-shATGL decreased media FAs in the presence of 2% 
BSA in the chase media (n=3). *P<0.05 vs. no BSA or shSCR and #P<0.05 vs. 
Ad-Null. (C) Transwell studies revealed that Ad-ATGL transduced donor 
hepatocytes released more BODIPY FAs to untransduced acceptor hepatocytes 
compared to the Ad-Null controls (n=3). (D) Inhibiting reuptake of expelled FAs 
using the FA uptake inhibitor CB16.2 (100 μM) along with BSA increased media 
FA content under basal and Ad-ATGL conditions (n=4). (E, F, G) The 
autophagosome-lysosome fusion inhibitor chloroquine, LIPA inhibitor (Lstat) or 
using a siRNA targeting LIPA lowered media FAs (n=3). (H) vacuolin 1 (75 μM), 
which inhibits lysosomal docking to the cell membrane, decreased media FAs in 
Ad-Null treated hepatocytes and largely blocked the induction of media FAs in 
hepatocytes overexpressing ATGL (n=6). (I) Imaging studies revealed a 
ballooning effect coupled with lipid accumulation within lysosomes 4 hours post 
vacuolin 1 (75 μM) treatment (n=3). For Figures D-H, *P<0.05 vs. Ad-Null and 
#P<0.05 vs. vehicle or siControl. (J) In vivo efflux of FAs from liver perfusates. 
Fasting and addition of 1% BSA significantly increased FA sequestration, which 
was further increased with the addition of 100 μM CB16.2 and negated in the 
presence of 75 μM vacuolin 1 (n=6). ^P<0.05 vs. -BSA,#P<0.05 vs. +BSA, 
$P<0.05 vs. BSA+CB16.2. 
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Figure 6. Expelled FAs require re-uptake before their subsequent 
metabolism.  
(A-B) vacuolin 1 (75 μM) prevented the loss in cellular TAG and oxidation of 
hydrolyzed FAs in response to ATGL overexpression (n=6). (C-D) Addition of 2% 
BSA to the chase and/or ATGL overexpression reduced [14C]TAG during the 
chase period and BSA attenuated the increase in oxidation of hydrolyzed FAs 
following ATGL overexpression (n=6). (E-F) Addition of 100 μM of CB16.2 
reduced [14C]TAG (E) and blocked the ATGL-mediated increase in oxidation of 
hydrolyzed FAs during the chase period (F) (n=4). (G) ATGL overexpression 
increased [3H]glycerol incorporation into cell TAG during the chase period, an 
effect that was blocked by the addition of 2% BSA alone or with 100 μM  CB16.2.  
Quantification data are from n=3.  For A-G, *P<0.05 vs.  Ad-Null and #P<0.05 vs. 
vehicle. (H) Incubation of hepatocytes during a 2-hour chase period with 
ATGListatin or LAListat in the presence of the FA reuptake inhibitor CB16.2 has 
a significant but subtle effect on the oxidation of hydrolyzed FAs (n=3). *P<0.05 
vs. DMSO and #P<0.05 vs. CB16.2. (I) BSA independently or in combination with 
CB16.2 and vacuolin 1 lowered β-hydroxybutyrate concentrations in the 
perfusate (n=6). ^P<0.05 vs. –BSA, #P<0.05 vs. +BSA.  
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Figure 7. ATGL promotes FA oxidation and autophagy/lipophagy. 
(7A) Ad-shATGL treated mice had lower levels of hepatic LAMP1 protein (n=2); 
*P<0.05. (7B) MEFs were transfected with GFP-LC3 and starved in Earle’s 
Balanced Salt Solution (EBSS) for 2 hours. GFP punctae are visible in the DMSO 
treated cells and are lost with ATGListatin treatment (n=2); *P<0.05. (7C) Primary 
hepatocytes cultured in EBSS for 2 hours with DMSO or ATGListatin and stained 
for lysosomes (LAMP1) and LDs (PLIN2). Colocalization between LAMP1 and 
PLIN2 was reduced with ATGListatin treatment (n=3). (7D) Ad-ATGL treated 
mice had increased hepatic LAMP1 protein. 
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Figure 8. SIRT1 inhibition impairs ATGL-mediated autophagy/lipophagy. 
(8A) The induction in autophagy gene expression in response to ATGL 
overexpression is attenuated with SIRT1 knockdown. Mice were treated with 
adenoviruses harboring SIRT1 shRNA, ATGL or their respective controls I week 
prior to sacrifice (n=5); *P<0.05 vs. Ad-Null and #P<0.01 vs. shSCR. (8B) 
shSIRT1 treated livers had reduced levels of Lamps; a representative western 
blot from 2 mice is shown. (8C) Western blot showing SIRT1 and ATGL protein 
levels in hepatocytes treated with shSIRT1 and ATGL adenoviruses; a 
representative western blot from 3 hepatocyte experiments is shown. (8D) 
Colocalization between lysosomes and LDs in hepatocytes treated with dual 
viruses harboring shSCR/shSIRT1 and Ad-Null/Ad-ATGL (n=3); p<0.001. (8E) 
Hepatocytes transfected with dual sensor LC3 and treated with 10 mM EX527, 
reveal impaired autophagic flux upon SIRT1 inhibition, which blocked the 
increase in flux following ATGL overexpression (n=3). 
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Figure 9.  ATGL-driven FA efflux is mediated via the lysosome. 
(9A) Western blot confirmation of ATGL overexpression in LIPA-/- livers. (9B) 
TAG hydrolase assay in ATGL overexpressing livers from LIPA-/- mice. (9C) 
Efficacy of siLIPA in primary mouse hepatocytes 60 hours post transfection; a 
representative western blot from 2 replicates in shown. (9D) A transwell 
experiment in primary mouse hepatocytes show that the Ad-ATGL transduced 
donor cells FA efflux and storage in acceptor cells which is blocked with the 
addition of 75μM vacuolin 1 (n=3). (9E) Increased C12-BODIPY (558/568) within 
lysosomes following 75μM vacuolin 1 (n=3). (9F) Addition of 10μM HTS, a pan-
FABP inhibitor, did not influence FA efflux (n=3); *P<0.01 vs. Ad-Null. (9G) 
Chronic inhibition of ATGL using Ad-shATGL in combination with LAListat 
reduces FA efflux of hydrolyzed FAs. (9H) Addition of ATGListatin or LAListat in 
the presence of FA reuptake inhibitor CB16.2 reduces the accumulation of FAs in 
the media (n=3 for 9G and 9H); P<0.005.  
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Figure 10. Sphingomyelins alter lysosomal signaling and subsequent 
media FA efflux. 
(10A-B) Heat maps or individual lipid quantification generated from lipidomic 
analysis of livers from scrambled control or ATGL knockdown virus treated livers 
reveal increased sphingomyelin accumulation in shATGL treated livers (n=7); 
*P<0.05 vs. shSCR. (10C) Lysosomal and golgi-specific genes involved in 
sphingomyelin hydrolysis are lower in the absence of hepatic ATGL (n=6); 
*P<0.05 vs. shSCR. (10D) Media FA levels are increased following treatment 
with MLSA1, a TRPML1 agonist, and reduced following treatment with SM 
(d18:1/16:0), a TRPML1 antagonist. Representative radiographs of FAs are 
shown and quantification data are from n=3; *P<0.05.  
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DISCUSSION 
Herein, we define a previously unrecognized interplay between ATGL-
catalyzed lipolysis and autophagy.  We show that ATGL promotes 
autophagy/lipophagy, which in turn catalyzes the catabolism of LDs.  Additionally, 
SIRT1 plays a critical role in linking ATGL signaling to the increase in 
autophagy/lipophagy.  Finally, we characterize the importance of lysosomal 
fusion to the plasma membrane and FA efflux as an important pathway 
influencing hepatic energy metabolism.   
The past decade has seen significant advances in our knowledge about the 
molecular mechanism of autophagy and its role in the pathophysiology of 
multiple disorders.  Despite a long known linkage between LIPA deficiency and 
steatosis in humans (Burke and Schubert, 1972), lipophagy has only recently 
been shown to contribute directly to hepatic lipid catabolism (Singh et al., 2009). 
In addition, recent work has suggested that chaperone-mediated autophagy 
indirectly contributes to lipophagy in the liver.  Specifically, chaperone-mediated 
degradation of the LD proteins Perilipin 2 and Perilipin 3 promote increased 
access of ATGL to the LD surface to enhance lipolysis (Kaushik and Cuervo, 
2015).  The findings in the current study extend these data and suggest that the 
increase in ATGL activity promotes macro- and microlipophagy, which in turn are 
responsible for the catabolism of LDs.  In addition to ATGL containing LIR motifs 
(Martinez-Lopez et al., 2016), the studies with ATGListatin indicate that ATGL 
could influence lipophagy by providing a signal that allows for recognition of LDs 
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by autophagosomes and lysosomes in addition to the increased 
lipophagic/autophagic machinery. However, the mechanistic details through 
which lipophagy works are still being elucidated.  
ATGL is recognized to play a central role in lipolysis in many tissues.  
Upon lipolytic stimulation ATGL and additional lipolytic proteins are recruited to 
the LD surface to promote TAG hydrolysis (Coleman and Mashek, 2011).  
Although the hydrolyzed FAs would presumably be available to enter a myriad of 
potential metabolic pathways, numerous studies have shown that ATGL 
selectively channels hydrolyzed FAs to oxidative pathways (Ahmadian et al., 
2010; Ong et al., 2011; Wu et al., 2012). This selective partitioning of FAs to the 
mitochondria is reminiscent of starvation-induced autophagy, which supplies cells 
with substrates to generate energy in times of need.  Studies from our laboratory 
and others have shown that LDs interact with numerous organelles including 
mitochondria (Khan et al., 2015b; Pu et al., 2011; Wang et al., 2011), which is 
speculated to facilitate transfer of FAs for their subsequent oxidation (Herms et 
al., 2015; H. Wang et al., 2011). The data in the current manuscript suggest that 
FAs, especially in response to ATGL activity, are largely effluxed rather than 
released intracellularly.  Consistent with these data presented, overexpression of 
ATGL in McArdle-RH7777 cells, a hepatoma cell line, also promotes FA efflux 
(Reid et al., 2008), while studies in fibroblasts show that the efflux of FAs is 
mediated via the lysosome (Groener et al., 1996).  While we cannot rule out 
some contribution of intracellular FA flux to the mitochondria directly from LDs 
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(Rambold et al., 2015) our data clearly support a model where FAs stored in LDs 
under lipophagy-mediated efflux prior to subsequent oxidation or entrance into 
other metabolic pathways. Thus, it is plausible that efflux of FAs us a protective 
mechanism to reduce lipotoxicity or, alternatively, act as a means to redistribute 
energy to adjacent cells.  
Several studies have also demonstrated that SIRT1 is an important 
regulator of autophagy.  SIRT1 deacetylates several mediator proteins of 
autophagy such as ATG5, ATG7 and ATG8/LC3 (Lee et al., 2008) and regulates 
the transcriptional control of autophagy via numerous transcription factors and 
coactivators including PGC-1α and PPARα.  Several similarities were observed 
between the SIRT1-/- and ATG5-/- mice, especially the accumulation of damaged 
mitochondria and deficiency in energy metabolism (Lee et al., 2008).  Our 
laboratory has shown that liver-specific deletion of ATGL results in lipid 
accumulation with a concomitant decrease in SIRT1 activity, PPAR-α/PGC-1α 
target gene expression and downstream mitochondrial biogenesis and β-
oxidation (Khan, et al., 2015; Ong et al., 2011). Thus, the ATGL-/- model appears 
similar to the SIRT1-/- and ATG5-/- mice with alterations in energy metabolism due 
to reduced mitochondrial capacity. The current experiments bridge these studies 
to show that SIRT1 mediates the effects of ATGL on autophagy/lipophagy 
induction.   Thus, these studies provide an additional mechanism through which 
SIRT1 is regulated, in this case via ATGL-catalyzed lipolysis, to influence 
downstream metabolism. 
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Our lipidomic analysis shows that ATGL deletion results in sphingomyelin 
accumulation. These differences in lipids are attributed to altered gene 
expression of the acid (lysosome-specific) and neutral (Golgi-specific) 
sphingomyelinase enzymes.  Most lysosomal storage diseases are due to the 
defective activity of various lysosomal enzymes resulting in accumulation of 
specific lysosomal substrates or impaired lipid trafficking as seen in diseases like 
Niemann Pick Disease Type A, B and C (Schuchman, 2010; Vitner et al., 2010).  
Sphingomyelins have been shown to negatively regulate the specific lysosomal 
Ca2+ channel, TRPML1, which is also compromised in lysosomal storage 
disorders (Kiselyov et al., 2010; Shen et al., 2012).  We believe that this 
accumulation of sphingomyelin within the lysosomes could be contributing to the 
impaired FA efflux (via TRPML1 inhibition) observed in cells lacking ATGL 
(Schuchman, 2010; Shen et al., 2012) in addition to the reduced flux of FAs 
through the lipophagy pathway.  
Our data suggest that ATGL is not directly responsible for the mass 
breakdown of LDs in the liver.  Rather, ATGL acts as in important signaling node 
that promotes autophagy/lipophagy, which in turn catalyzes the majority of LD 
catabolism.  This study also highlights the importance of FA efflux as in 
intermediate step in the catabolism of lipids in the liver.  In sum, we provide new 
insights into the regulation of hepatic lipid and energy metabolism, which 
underpins non-alcoholic fatty liver disease and related hepatic diseases.   
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Non-alcoholic fatty liver disease (NAFLD), representing the hepatic 
manifestation of the metabolic syndrome, is the most common chronic liver 
disease worldwide.  NAFLD can progress from steatosis (characterized by 
fat/triacylglycerol (TAG) accumulation in >5% of the parenchymal 
cell/hepatocytes), to increased inflammation and fibrosis resulting in non-
alcoholic steatohepatitis, and finally to cirrhosis leading to hepatocellular 
carcinoma and liver death (Satapathy and Sanyal, 2015). Although previously 
under-recognized, the accumulating evidence that suggests progression from 
NAFLD to NASH puts a large number of patients at risk for chronic and 
debilitating liver disease (Agrawal and Duseja, n.d.). Statistics show that about 3 
million new NAFLD cases are diagnosed in the United States annually with over 
2 billion occurrences worldwide (Katsiki et al., 2016; Satapathy and Sanyal, 
2015).  Furthermore, there are no pharmacological options for NAFLD, and the 
recommended therapy includes lifestyle modifications through diet reduction, an 
exercise regimen, and weight loss although the efficacy of this regiment is low 
(Katsiki et al., 2016).  In most cases, the etiology of NAFLD is not completely 
understood and is thought to precede the development of insulin resistance that 
often accompanies obesity, dyslipidemia and Type 2 Diabetes, encompassing 
the metabolic syndrome (Angulo, 2002; Cave et al., 2007; Lonardo et al., 2015). 
The prevalence of NAFLD is expected to rise and thus represents one of the 
biggest health care challenges in the foreseeable future (Cave et al., 2007; 
Katsiki et al., 2016; McCullough, 2004). 
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Given the prevalence and deleterious effects of NAFLD, it is of paramount 
importance to advance our understanding of the mechanism involved in hepatic 
TAG accumulation in order to prevent NAFLD development and progression. 
Since TAG accumulation in the liver stems from increased TAG synthesis, a 
large focus of research has been on elucidating the TAG synthesis pathway and 
its role in NAFLD etiology.  However, since the discovery of the enzyme adipose 
triglyceride lipase (ATGL) and its role in TAG breakdown (Zimmermann et al., 
2004), several reports have looked at the contribution of lipolysis in the etiology 
of NAFLD (Jha et al., 2013; Ong et al., 2011).  
Previous work in our laboratory identified that ATGL preferentially 
channels a fatty acid (FA) produced from lipolysis, which is responsible for the 
first step in fat breakdown towards β-oxidation in the mitochondria (Ong et al., 
2011). Additional work revealed that ATGL directly activates the protein 
deacetylase Sirtuin 1 (SIRT1), a critical nutrient sensor involved in gene 
regulation and post-translational modification of several targets (Khan et al., 
2015a). Specifically, we show that a FA oleate derived through ATGL-catalyzed 
lipolysis can directly bind and activate SIRT1 (unpublished). We utilized 
analytical platforms such as reversed phase high performance liquid 
chromatography (RP-HPLC) and cyclic dichroism binding assays and found that 
oleate induced SIRT1 enzyme activity in a dose incremental manner.   
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This data identifies, for the first time, a novel mechanism by which a 
lipolytic intermediate positively regulates SIRT1 activity. Oleate is a 
monounsaturated fatty acid (MUFA) found in abundance in olive oil and nuts, key 
constituents of the Mediterranean Diet. This diet incorporates healthy eating with 
portions of veggies, nuts, fruits, a splash of olive oil, and red wine. Research has 
shown that those who practice the Mediterranean Lifestyle – diet plus ample 
exercise – have reduced incidence of cardiovascular disease with enhanced 
cognitive function. We speculate that the above-defined regulation of SIRT1 
through increased oleate consumption coupled with fasting/exercise may be the 
principal mechanisms explaining the health benefits of the Mediterranean 
Lifestyle and for the first time may provide a biological explanation of how the 
Mediterranean Lifestyle leads to improved health and longer lifespan. 
Since lifestyle changes are already the current standard for NAFLD 
treatment, this understanding of the role of oleate in mediating NAFLD can be 
used in treatment guidelines. In 2012 the American Association for the Study of 
Liver Diseases and the American Gastroenterological Association published their 
recommendations on NAFLD management supporting the implementation of 
adequate lifestyle modifications (Chalasani et al., 2012). In this context, a 
Mediterranean diet in combination with exercise was shown to improve insulin 
resistance and hepatic steatosis in NAFLD patients (Mahady and George, 2016). 
Additionally, these beneficial effects were achieved in the absence of sustained 
weight loss (Ryan et al., 2013).   
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In addition to the above findings, we show that the key signaling node of 
ATGL-mediated induction of SIRT1 is also involved in autophagy induction. 
Specifically, we show that functional autophagy/lipophagy mediates the effects of 
ATGL on lipid droplet degradation in the liver. Our data shows that ATGL 
mediates FA efflux via lipophagy and lysosomal fusion to the plasma membrane 
in cells, before their subsequent fate-either oxidation or re-esterification into TAG 
stores. These findings support previous research from our lab where we show 
the liver FA binding protein is not required for ATGL-mediated β-oxidation or 
PPAR-α expression, suggesting an alternate mechanism to intracellular 
trafficking to FAs must exist (Ong et al., 2014). Thus in conclusion, we believe 
our studies have unraveled a unique signaling cascade that have transformed 
the way we think about hepatic lipid droplet catabolism and how it contributes to 
oxidative metabolism linking NAFLD and metabolic disease alleviation.  
NAFLD was first diagnosed in 1980 (Foster et al., 1980) and 35 years 
later, it is now recognized as the most common liver disease worldwide. 
Moreover, NAFLD is a strong determinant for the development of the metabolic 
syndrome. Previous research highlights that impaired insulin signaling in the 
adipose tissue results in increased lipolysis and FA release that subsequently 
enter the liver to promote hepatic TAG synthesis and NAFLD development 
(Gastaldelli et al., 2007).  However, our data now provides evidence for the 
potential of hepatic ATGL/lipolysis activators as a new class of novel therapeutic 
entities. Additional research will be required to develop and test small molecule 
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therapeutics that specifically target and activate ATGL as an effort to provide the 
foundation for novel future drug discovery efforts in this area.  
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